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Abstract 
Initially found to regulate G2/M cell cycle checkpoint upon irradiation-induced DNA 
damage, RINT1 (RAD50-interacting protein 1) was later shown to be a multifunctional 
protein. RINT1 participates in telomerase-independent telomere length maintenance, 
membrane trafficking between Golgi apparatus and endoplasmic reticulum and ER-Golgi 
homeostasis. Inactivation of Rint1 leads to an early embryonic lethality. RINT1 can act as 
tumor suppressor, since heterozygous inactivation results in tumor formation in mice, 
while in humans mutant RINT1 variants predispose to development of breast- and Lynch 
syndrome-related cancers. RINT1 was also proposed to be an oncogene for glioblastoma 
development. Nevertheless, despite its involvement in a variety of biological pathways, 
no data regarding post-translational modifications (PTM) of RINT1 or their impact on the 
protein’s function was reported. 
The present study shows that RINT1 is subjected to two kinds of post-translational 
modifications: ubiquitination and, putatively, SUMOylation. It was found that RINT1 is a 
short-lived protein with a half-life (approx. 40 min) regulated by a proteasomal 
degradation pathway. RINT1 is ubiquitinated by several ubiquitin linkage types. Since K48-
mediated polyubiquitin (polyUb) chains as well as K63- and K29-mediated polyUb chains 
were detected, functional significance of RINT1 ubiquitination is not limited to 
proteasomal degradation (K48-mediated polyUb chains) but could also serve to regulate 
multiple cellular functions of RINT1 (K63- and K29-mediated polyUb chains). Interestingly, 
RINT1 was also found to interact with lysineless ubiquitin mutant. Thus, 
monoubiquitination or linear ubiquitination (a less characterized and newly discovered 
PTM) of RINT1 could also be postulated. Furthermore, analysis of in silico predicted 
ubiquitination sites of RINT1 by co-immunoprecipitation of mutant versions (truncated 
mutants and site-directed mutagenesis) revealed that RINT1 is ubiquitinated at different 
sites within the protein. Two E3 ubiquitin ligases, HUWE1 and RNF20/RNF40E3 complex, 
were identified by mass spectrometry assay as binding partners mediating ubiquitination 
of RINT1. The specificity of these interactions was subsequently confirmed by co-
immunoprecipitation experiments. Importantly, shRNA-induced down-regulation of 
HUWE1 and RNF20 or RNF40 protein levels resulted in enhanced RINT1 stability, thus 
indicated their novel role as regulators of proteasomal degradation of RINT1. Moreover, 
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mass spectrometry analysis and yeast two-hybrid assay identified SUMOylation as 
another covalent modification of RINT1. First experiments suggested covalent 
modification of RINT1 by SUMO proteins. 
In conclusion, the present study demonstrated that human RINT1 is a protein of a short-
half life, heavily ubiquitinated at different sites within the protein and via different 
ubiquitin chain linkage types (K29, K48, K63). It is also modified by a lysineless ubiquitin 
mutant and potentially SUMOylation. Importantly, RINT1 interacts with HUWE1 and 
RNF20/40 E3 ubiquitin ligases, which tightly control its cellular levels. This study reveals 
crucial mechanisms governing homeostatic RINT1 turnover and, in this respect, is the first 
to address the presence and functionality of RINT1 polyubiquitination. 
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Zusammenfassung 
Nachdem zunächst festgestellt wurde, dass RINT1 (RAD50-interacting-Protein 1) den 
G2/M-Zellzyklus-Kontrollpunkt nach DNA Schäden durch Bestrahlung reguliert, wurde 
später herausgefunden, dass RINT1 ein multifunktionelles Protein ist. So beteiligt sich 
RINT1 an der Telomerase unabhängigen Aufrechterhaltung der Telomerlänge sowie an 
Membrantransport zwischen Golgi-Apparat und endoplasmatischem Retikulum und 
deren Homöostase. Inaktivierung von Rint1 führte zu einer frühen embryonalen 
Sterblichkeit, während sie im Menschen zu einer Prädisposition für Brustkrebs und dem 
Lynch-Syndrom beiträgt. Auch wird vermutet, dass RINT1 als Onkogen in der Entstehung 
von Gliomen mitwirkt. Trotz der Beteiligung an einer Vielzahl biologischer Prozesse gab es 
bisher keine Daten zu post-translationalen Modifikationen (PTM) von RINT1 und deren 
Auswirkung auf die Funktionen des Proteins.    
Die vorliegende Studie zeigt, dass RINT1 zwei Arten von PTM unterzogen wird: 
Ubiquitinierung und gegebenenfalls SUMOylierung. Es wurde festgestellt, dass RINT1 ein 
kurzlebiges Protein mit einer Halbwertszeit von ca. 40 Minuten ist, welche durch 
proteosomalen Abbau reguliert wird. RINT1 wird auf verschiedene Weisen ubiquitiniert. 
So konnten sowohl K48-verknüpfte Polyubiquitin (polyUb) Ketten als auch K63- und K29- 
verknüpfte polyUb Ketten nachgewiesen werden. Dies deutet darauf hin, dass 
Ubiquitinierung von RINT1 nicht nur dessen proteosomalen Abbau reguliert (vermittelt 
durch K48-verknüpfte polyUb Ketten) sondern außerdem an der Regulation weiterer 
biologischer Prozesse beteiligt ist (vermittelt durch K63- und K29-verknüpfte polyUb 
Ketten). Interessanterweise konnte außerdem eine Interaktion von RINT1 mit Lysine-
freien Ubiquitin-Mutanten nachgewiesen werden. Dies lässt sowohl Monoubiquitinierung 
als auch lineare Ubiquitinierung (eine weniger charakterisiert und neu entdeckte PTM) 
von RINT1 vermuten.  
Des Weiteren bestätigte die Analyse von in silico vorhergesagten Ubiquitinierungsstellen 
mittels Co-Immunpräzipitation mutierter RINT1-Varianten, dass RINT1 an verschiedenen 
Stellen innerhalb des Proteins ubiquitiniert wird. Zwei E3 Ubiquitin-Ligasen, HUWE1 und 
RNF20/RNF40E3-Komplex, konnten mittels Massenspektrometrie als Bindungspartner 
von RINT1 und Vermittler der Ubiquitinierung identifiziert werden. Die Spezifität der 
Interaktionen wurde anschließend durch Co-Immunpräzipitation bestätigt. Die shRNA-
Zusammenfassung 
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induzierte Reduktion von HUWE1, RNF20 sowie RNF40 resultierte in einer erhöhten 
Proteinstabilität von RINT1. Dies bestätigt die bislang  unbekannte Rolle dieser Proteine 
als Regulatoren des proteosomalen Abbaus von RINT1. Des Weiteren konnte in 
massenspektrometrischen Analysen sowie mittels yeast two-hybrid-assay SUMOylierung 
von RINT1 als eine weitere kovalente Modifikation identifiziert werden. Diese Ergebnisse 
wurden mit initialen Versuchen angedeutet.  
Zusammenfassend zeigt die hier vorliegende Studie, dass humanes RINT1 ein Protein mit 
kurzer Halbwertszeit ist, welches an verschiedenen Stellen innerhalb des Proteins und 
über verschiedene Ubiquitinierungsarten (K29, K48, K63) modifiziert wird. Zusätzlich wird 
RINT1 auch durch eine Lysine-freie Ubiquitin-Mutante sowie potenziell SUMOylierung 
modifiziert. RINT1 interagiert mit den E3-Ubiquitin-Ligasen HUWE1 und RNF20/40-
Komplex, wodurch die Stabilität des Proteins reguliert wird. 
Die vorliegende Studie beschreibt essentielle Mechanismen der homöostatischen 
Regulation von RINT1 und belegt in diesem Zusammenhang erstmals sowohl 
Vorhandensein als auch Funktionalität von Polyubiquitinierung von RINT1 als 
verantwortliche post-translationale Modifikation. 
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Aim of the study  
Post-translational modifications (PTMs) constitute a powerful biochemical tool to modify 
functions, interactions and localization of a modified protein. PTMs are especially 
important to diversify cellular roles of a given protein by providing precise regulation and 
flexibility to perform different functions. 
RINT1 (RAD50-interacting protein 1) is a multifunctional protein, which plays an 
important role in the cell cycle regulation, telomere length maintenance and ER-Golgi 
trafficking. Recently, it was shown to act as a both proto-oncogene and tumor supressor. 
Despite its involvement in such diverse processes nothing is known about the PTMs of 
RINT1, which could regulate and drive the possibility of executing such spatially and 
temporally distinct cellular functions of the protein.  
The objective of the current experimental study was: (1) to investigate and characterize 
PTMs of RINT1 as well as (2) to reveal novel proteins interacting with RINT1 able to 
mediate its modifications. The obtained data would help to understand the regulation of 
RINT1 functions and to further define other putative biological roles of RINT1 protein. 
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1. Introduction 
1.1. General characteristics of RINT1 protein 
Human RINT1 (RAD50-interacting protein 1) is a 90 kDa (NCBI Ref. Seq. NP_068749.3) 
protein, encoded by the RINT1 gene located on the chromosome 7 in humans (long arm; 
7q22.3) and chromosome 5 in mice (5 A3, 5). It was discovered as an interaction partner 
of RAD50 during late S and G2/M phases of the cell cycle (Xiao, Liu et al. 2001). Although 
almost 14 years have passed since this initial finding, still surprisingly little is known about 
biochemical features and exact cellular functions of RINT1 protein. Of note, very recent 
reports addressing a pivotal role of RINT1 in tumorigenesis, call for more detailed 
biochemical studies of this protein. 
RINT1 is expressed throughout the cell cycle and localized in the cytoplasm, endoplasmic 
reticulum (ER), Golgi apparatus and centrosome (Xiao, Liu et al. 2001; Hirose, Arasaki et 
al. 2004; Nakajima, Hirose et al. 2004; Kong, Meloni et al. 2006). Due to its reported 
association with DNA double-strand brakes repair complex and function in maintenance 
of telomere length, the nuclear localization of human RINT1 could also be possible (Xiao, 
Liu et al. 2001; Kong, Meloni et al. 2006). Despite localization of RINT1 protein at the ER 
and Golgi membranes, RINT1 itself is not considered to be a trans-membrane protein or 
protein directly associated with the membrane. Experimental results indicate that RINT1 
binds to cellular membrane structures via protein interaction partners. In that respect, 
RINT1 interacts with BNIP1, ZW10 and NAG proteins forming a NRZ (NAG-RINT1-ZW10) 
complex associated with ER SNARE (Hirose, Arasaki et al. 2004; Aoki, Ichimura et al. 2009; 
Schmitt 2010; Tagaya, Arasaki et al. 2014). This conclusion is supported by in silico 
predictions of hydrophobicity (Kyte & Doolittle) and transmembrane regions of RINT1 
(Fig. 1). It Is apparent that no trans-membrane helices of hydrophobic patches 
reminiscent of transmembrane regions could be identified. Summary of known features 
of RINT1 protein and comparison between human and mouse RINT1 are presented in 
Table 1. Interestingly, in human only one isoform of RINT1 have been identified, while in 
mouse, at least two isoforms of the protein have been described. They are a result of an 
alternative splicing and differ in 58 amino acids (172 – 229), which are missing in isoform 
2 (source: Uniprot). 
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Figure 1. RINT1 is not predicted to be a membrane protein. Hydrophobicity plots and 
transmembrane region prediction generated with ProtScale (Gasteiger, Gattiker et al. 2003) 
(upper panel, window size applied = 17) and TMHMM online software (Krogh, Larsson et al. 2001) 
(lower panel).  
Table I. Features of human and mouse RINT1/Rint1. 
Feature Homo sapiens, Human Mus musculus, Mouse 
Size 792 amino acids, 90 kDa 792 amino acids, 90 kDa 
Genomic location 7q22.3 5 A3, 5 
Cellular location ER, cytoplasm, Golgi, 
centrosome 
ER, cytoplasm 
Domain RINT1/TIP20 
Position: 304 - 785 aa 
RINT1/TIP20 
Position: 220 - 792 aa 
Coiled coil Position: 103 – 124 aa Position: 71 – 123 aa 
Source: UniProt database (www.uniprot.org) 
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1.1.1. Functional RINT1 domains 
Several functional and two sequence/structure prediction-based domains have been 
identified in RINT1. First, a coiled coil (CC) structural motif has been localized between 
amino acids (aa) 103 and 124 (Table I, UniProt). It is built of alpha-helices forming a 
supercoil structure potentially suitable for mediating protein-protein or protein-DNA 
interactions (Burkhard, Stetefeld et al. 2001). A RINT1-characteristic aa stretch from 
position 220 to 792 was designated as “RINT1/TIP20 domain” on the basis on the high 
evolutionary conservation of the aa sequence (Fig. A-6, Appendix).  
At the functional level, Xiao et. al. reported that RINT1 interaction with RAD50 is 
mediated by protein region at position 257-792 aa (“RAD50 interaction domain”) (Xiao, 
Liu et al. 2001). Similarly, Kong et. al. identified the “p130 interaction domain” – position 
358-440 aa (Kong, Meloni et al. 2006). Moreover, aa stretch 1-264 identified as the 
“ZW10 interaction domain” by Arasaki et. al. was also reported to be the “COG1 
interaction domain” (conserved oligomeric Golgi complex subunit 1) and the “syntaxin 16 
interaction domain”. (Arasaki, Taniguchi et al. 2006; Arasaki, Takagi et al. 2013). 
Interestingly, since interactions with ZW10, COG1 and syntaxin 16 are all encompassing 
CC domain, functional role of the CC structure for mediating protein-protein interaction is 
highly probable. Figure 2 aligns in graphical way all identified domains of human RINT1 
protein. 
 
 
 
Figure 2. Alignment of functional and “sequence/structure-prediction”-based domains of 
human RINT1. 
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1.1.2. RINT1 post-translational modifications 
On the basis of published high throughput screens, only few data point towards 
possibility of post-translational modifications (PTMs) of RINT1. One study reported two 
putative ubiquitination sites of Rint1, on lysine 69 (Lys69) and on lysine 502 (Lys502), 
based on proteomic analysis of murine tissue (Wagner, Beli et al. 2011). Subsequent 
analysis of human multiple myeloma cell line AMO-1, confirmed Lys502 ubiquitination of 
RINT1 (PhosphoSitePlus database, www.phosphosite.org). 
There are few reports regarding phosphorylation of RINT1 protein. Two of them showed 
modification on serine residue (Ser) at position 10, based on mass spectrometry (MS) 
analysis of proteins from human male urine sample (Human Proteinpedia, HuPA_00021) 
and of human cervical cancer HeLA cell line (Sharma, D'Souza et al. 2014). Another piece 
of data suggesting phosphorylation originated from the in-depth analysis of human liver 
phosphoproteome and suggested Ser19 to be a phosphorylated residue (Bian, Song et al. 
2014). According to MS analysis of human gastric carcinoma samples, threonine (Thr) 94, 
Ser96 and Ser97 are also subjected to phosphorylation (PhosphoSitePlus database, 
www.phosphosite.org; NAR, 2012,40:D261-70). Last evidence towards human RINT1 
phosphorylation came from the study of Jurkat cell line derived from human T-
lymphocyte acute lymphoblastic leukemia (T-ALL). Based on MS data, Ser635 and Thr654 
were considered as phosphorylated (PhosphoSitePlus database). Figure 3 summarizes all 
putative PTMs of Rint1 suggested by the high throughput screen data. 
 
 
 
 
Figure 3. MS-based ubiquitination and phosphorylation sites of RINT1. Scheme represents 
positions of modified residues: green – ubiquitination (U) on lysine residues, red – 
phosphorylation (P) on serine residues, blue – phosphorylation (P) on threonine residues. 
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1.1.3. Phylogenomic analysis of homology and conserved, putative 
PTMs of RINT1 
RINT1 is a prototypic protein of a RINT1 protein family. Its members share sequence 
similarity with an N-terminal leucine heptad repeat rich coiled, and contain carboxy-
terminal “RINT1/TIP20 domain” of ~500-residue length. In general, these proteins play a 
role in retrograde and anterograde transport between the ER and the Golgi. Besides 
RINT1, other members are: mouse Rint1 protein (Mus musculus), MAG2 (MAIGO2) and 
MAG2L protein of Arabidopsis thaliana, and RINT1-like protein encoded by the gene 
CG8605 in Drosophila melanogaster. In Arabidopsis, MAG2 has a function in transport of 
storage protein precursors between the ER and Golgi (Li, Shimada et al. 2006). TIP20 
(Tip20) is RINT1 orthologue in yeasts (Saccharomyces cerevisiae) and it plays a role in the 
retrograde transport from the Golgi to ER (Sweet and Pelham 1993; Tripathi, Ren et al. 
2009). 
Phylogenetic tree prediction, based on amino acid sequences of RINT1 homologs, is 
presented in Figure 4. 
 
 
 
 
 
 
 
Figure 4. The phylogenetic tree of RINT1 protein. The analysis was performed on the 
Phylogeny.fr platform (http://phylogeny.lirmm.fr/). The line with the number “0.5” shows the 
length of branch representing an amount of genetic modification of 0.05 [nucleotide substitution 
per site]. The phylogenetic tree was reconstructed using the maximum likelihood method 
implemented in the PhyML program (v3.0). Graphical representation and edition of the 
phylogenetic tree were performed with the TreeDyn (v198.3) (Castresana 2000; Edgar 2004; 
Anisimova and Gascuel 2006; Chevenet, Brun et al. 2006; Dereeper, Guignon et al. 2008; Guindon, 
Dufayard et al. 2010). 
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Highly evolutionary conserved “RINT1/TIP20 domain” region could be of potential 
meaning for the identification of residues modified by PTMs. In silico prediction of 
modified residues indicates that RINT1 homologs share evolutionary conserved putative 
post-translational modification sites. Figure 5 depicts the identified positions and 
postulated modifications.  
 
 
 
 
 
 
 
 
 
Figure 5. Example of evolutionary conserved RINT1 post-translational modification sites and 
their localization. The predicted modification sites are indicated: phosphorylation (P), 
ubiquitination (U) and SUMOylation (S). The number indicates position of the PTM on the human 
RINT1 amino acid (aa) sequence. The most conserved aa is lysine on the position 449 (K449) and is 
predicted to be SUMOylated (S449) and ubiquitinated (U449) (courtesy of Dr. P. Grigaravičius). 
 
1.1.4. RINT1 expression pattern in human tissues 
High-throughput gene expression profiling allows investigation of transcriptional activity 
in biological samples of different organisms on a genome scale. Analysis of normal or 
cancerous tissues, organs or cell lines, gives a tissue-specific pattern of mRNA expression, 
which can indicate function of the protein encoded by a given gene.  
The examination of RINT1 expression pattern (high-density oligonucleotide arrays; BioGPS 
database, http://biogps.org) showed that the gene is highly expressed in nervous system, 
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especially in superior cervical ganglion (a part of the autonomic nervous system), skeletal 
muscle as well as in immune cells (B-lymphocytes, T-lymphocytes, dendritic cells). The 
RINT1 expression higher than average was detected in: tonsil, adrenal cortex, pituitary, 
fetal thyroid, pancreatic islet, Leydig and interstitial testis cells, smooth muscle, thyroid, 
liver, heart, uterus corpus, appendix, tongue, retina, in colorectal carcinoma and Burkitts 
lymphoma. 
These results are mostly overlapping with gene expression data stored in another 
database, Genevestigator (http://Genevestigator.com). According to collected results, 
RINT1 is highly expressed in B-lymphocytes, T-lymphocytes, skeletal muscle, heart, brain, 
eye, salivary gland, colon, rectum, liver, pancreas and macrophages. Figure 6 represents 
exemplary tissues and cells with medium and high expression of the human RINT1 gene. 
Interestingly, data deposited in Genevestigator concerning RINT1 expression in cancers, 
showed its medium to high expression in almost all cancer types, with particularly 
significant expression potential in colon, liver and pancreas cancers, neoplasms of 
respiratory system, bone cancers, eye, brain and central nervous system cancers, 
lymphomas and leukemias. 
To judge on their physiological relevance, the gene expression data have to be validated 
on a protein level. Thus, according to mass spectrometry analyses of the proteome 
deposited in the MOPED (Multi-Omics Profiling Expression Database) database 
(www.proteinspire.org), human RINT1 protein is expressed in following tissues: bone, 
testis, olfactory epithelium, stomach, adrenal gland, liver, rectum, pancreas, colon, 
salivary, thyroid and adrenal glands, esophagus, frontal lobe, spinal cord, retina, lung, 
lymph node, B- and helper T-lymphocytes, blood platelet, peripheral blood mononuclear 
cells, natural killer cell, ovary, placenta, pre-menopause uterus, breast cancer tissue, 
fetal: ovary, testis, heart, gut and liver. 
Therefore, it could be stated that RINT1 gene expression pattern corresponds well with 
tissue distribution of RINT1 protein. 
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A. 
 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
Figure 6. Genevestigator database data showing RINT1 expression in selected cells and tissues. 
A. RINT1 expression levels higher than average were found in liver, eye, leukocytes and parotid 
gland.  B. Cancer tissues analyzed reveal high expression of RINT1 in infiltrating duct carcinoma, 
chronic myelogenous leukemia, adenoma, glioblastoma and chronic lymphocyte B-cell leukemia.   
 
In conclusion, these data indicate that RINT1 is present in tissues of high metabolic rate, 
i.e. heart, liver, brain and skeleton muscle tissue. In addition, presence of RINT1 in cells 
and tissues, such as nervous system, T-cells and B-cells, support described RINT1 function 
in cell division (e.g. rapid proliferation of T-cells and B-cells upon antigen-induced 
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activation) and membrane trafficking (e.g. antibody production in B-cells and vesicular 
trafficking at synaptic terminals of neurons). 
 
1.2. Cellular roles of RINT1 
Current knowledge about RINT1 functions in, based on miscellaneous research results 
and places RINT1 amongst multifunctional proteins, participating in very different, 
spatially and temporarily separate biological pathways. This diversity of RINT1 functions 
depends on its interactions with various protein-partners, and on the cellular localization. 
Identified in 2001 as a RAD50-interactor, RINT1 was described for the first time as a 
protein involved in DNA damage-induced cell cycle checkpoint (Xiao, Liu et al. 2001). 
Further research studies highlighted its role in other biological processes, such as 
membrane trafficking (Hirose, Arasaki et al. 2004; Arasaki, Taniguchi et al. 2006; Lin, Liu et 
al. 2007; Sun, Shestakova et al. 2007; Arasaki, Takagi et al. 2013) and telomere length 
maintenance (Kong, Meloni et al. 2006). RINT1 was also reported to be an oncogene and 
a tumor suppressor gene (Lin, Liu et al. 2007; Quayle, Chheda et al. 2012; Park, Tao et al. 
2014). 
 
1.2.1. RINT1 function in DNA repair and double-strand breaks (DSBs)-
induced cell cycle checkpoints 
 
In the context of a known role of RINT1 in the maintenance of DNA integrity, particularly 
interesting cellular processes are: repair of double strand DNA breaks (DSBs), control of 
G2/M cell cycle checkpoint (Hoeijmakers 2009; Deckbar, Jeggo et al. 2011) and the 
process of DNA mismatch repair (Park, Tao et al. 2014). 
 
1.2.1.1. DBSs-induced cell cycle checkpoints and DNA mismatch 
repair (MMR) 
As a result of natural metabolic activity of the cells, as well as of the chemical and physical 
environmental factors, genetic information is exposed to potentially harmful molecular 
lesions every single day. Once DNA mutation is not properly repaired, it might be 
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accumulated and lead to premature cell aging or, in case of proliferating cells, be 
transmitted to the daughter cells during mitosis, thus causing genomic instability. 
Consequently, at the level of an organism, unrepaired DNA lesions may lead to  
tumorigenesis, and finally to death. Therefore, permanently active cellular DNA repair 
processes are necessary to preserve genetic information from destruction, and to restore 
damaged DNA. Efficient and accurate systems of the DNA damage responses (DDRs), 
protect genome integrity and guarantee functionality of the cell and accurate cell division 
(Branzei and Foiani 2008; Ciccia and Elledge 2010). In the course of evolution, cells have 
developed a number of signaling pathways providing efficient and precise DDRs. 
Following the detection of DNA damage, molecular complex signaling induces activation 
of corresponding cell cycle checkpoint (Fig. 7). 
The cell cycle checkpoints are specific time-points of the cell cycle, at which it can be 
stopped if the preceding phase hasn’t been properly completed, e.g. as a consequence of 
damaged DNA. There are several cell cycle checkpoints: the G1 checkpoint, named also 
restriction checkpoint in mammals or start checkpoint in yeast (checking for the DNA 
damage, cell size, nutrients and growth factors), the G2/M checkpoint (controlling proper 
DNA replication and cell size), the spindle assembly or metaphase checkpoint (supervising 
chromosome attachment to spindle), and the intra-S-phase checkpoint (checking for 
chromosomal DNA structures and replication) – depicted in Fig. 7. Efficient and proper 
mechanism of the cell cycle control is assured by the family of serine-threonine kinases 
called cyclin-dependent kinases (CDKs), activated upon their interaction with specific 
cyclins. For example, the main cyclin-CDK complex driving the G2/M cell cycle checkpoint 
is Cyclin B-cdc2 (CDK1) complex. When activated, CDKs subsequently activate their 
substrates characteristic for the specific cell cycle phase and release cascade of 
downstream processes promoting cell cycle progression.  
If the DNA damage occurs and the cell cycle checkpoint is activated, the activity of cyclin-
CDKs complexes driving cell cycle transitions is restrained. As a consequence, cell cycle is 
arrested in G1- (the G1 checkpoint) or G2-phase (the G2/M checkpoint), or the replication 
in S-phase is slowed down (intra-S checkpoint). This mechanism allows to repair DNA 
damage and resume the cell cycle, or to completely exit the cell cycle, if the lesions are 
irreparable (Branzei and Foiani 2008; Shaltiel, Krenning et al. 2015). 
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Figure 7. Cell cycle checkpoints. Cell cycle checkpoints assure proper cell cycle progression by 
monitoring the status of completion of the preceding phase. 
 
Cellular DDR depends both on the stage of the cell cycle, as well as on the character of the 
DNA damage. There are few common types of DNA damages, which are: base 
modification, mispairs, cross-linked nucleotides or double-strand DNA breaks (DSBs).  
DSBs are especially harmful type of lesions, as they can contribute to structural 
rearrangements and chromosome missegregation (Hoeijmakers 2009). Response to DSBs 
in G2-phase induces reversible cell cycle arrest , preventing cell from entering mitosis (M-
phase), thereby blocking proliferation of the cell with damaged genomic DNA. DNA repair 
machinery fixes the damage, mainly by homologous recombination repair (HRR) or non-
homologous end joining (NHEJ). The cell can also exit the cell cycle to undergo apoptosis, 
if the damage is irreparable (Liang, Deng et al. 2005; Klein, Hoffmann et al. 2015).  
Activation of the cellular response to DSBs in G2 phase occurs through the recognition of 
the DNA damage by the MRN complex (proteins: MRE11, RAD50 and NBN), followed by 
the recruitment and activation of the checkpoint kinase ATM (ataxia telangiectasia 
Intra-S 
Checkpoint 
Spindle assembly 
Checkpoint 
G2 Checkpoint 
G1 Checkpoint 
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mutated), which phosphorylates and activates its downstream targets (Fig. 8). This 
particular molecular pathway involves following steps: amplification of the signal by 
mediator proteins (MDC1, 53BP1, MRN complex, BRCA1), phosphorylation of checkpoint 
kinases CHK1 and CHK2, and phosphorylation of M-phase inducer phosphatase 3, 
CDC25C. Under normal conditions, non-phosphorylated CDC25 removes inhibitory 
phosphate residues from the Cyclin B-CDK1 complex. Dephosphorylation activates the 
complex thereby triggers entry into the next phase of the cell cycle, the mitosis (Fig. 8). 
Phosphorylation of active CDC25C by CHK1 inhibits its activity and, as a consequence, 
Cyclin B-CDK1 remains phosphorylated by protein kinase WEE1, thus inactive. The 
transition from G2 to M phase is inhibited. The block of CDK1 function is the most 
essential stage of this pathway (Lobrich and Jeggo 2007; Matsuoka, Ballif et al. 2007; 
Ciccia and Elledge 2010; Langerak and Russell 2011). 
One of the key-regulators of DNA repair and stress-induced cell cycle arrest is the p53 
protein, which levels are regulated by Mdm2 E3 ubiquitin ligase. The role of p53 in the 
regulation of the cell entry into mitosis is well established. DNA damaging factors, such as 
UV or ionizing radiation, activate the DDR; ATM/ATR kinases phosphorylate p53 protein 
directly, or activate CHK2 kinase also phosphorylating p53. Modification of p53 activates 
the protein and leads to its stabilization and induction of its DNA binding activity and 
transcriptional regulatory response. Moreover, upon activation p53 indirectly inhibits 
cdc2, required for entering the mitosis, by regulating three targets: (i) 14-3-3, which binds 
to phosphorylated Cyclin B-cdc2 complex and exports it from the nucleus, (ii) GADD45, 
binding and dissociating Cyclin B-cdc2 complex, and (iii) p21 Cip1, inhibiting several CDKs, 
and among them cdc2 (Taylor and Stark 2001; Hein, Ouellette et al. 2014). 
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Figure 8. Molecular pathway of double-strand breaks (DSBs) repair and G2/M checkpoint 
activation (adapted from Löbrich et al. (Lobrich and Jeggo 2007)). ATR protein responds to single 
stranded DNA. 
 
DNA damages that occur during DNA replication and recombination, such as small 
insertions, small deletions or base-base mismatches (G/T or A/C pairing), are repaired via 
the DNA mismatch repair (MMR) pathway. This allows for genomic stability maintenance 
by control of the cell cycle arrest and cell death. The mechanism of DNA mismatch repair 
was investigated and described in great details based on the studies in E. coli. 
Nevertheless, as a highly conserved process, MMR exhibits substantial similarities 
between E. coli and human, i.e. in substrate specificity and bi-directionality. Briefly, the 
process of MMR in humans begins with the detection of damaged DNA fragment by the 
MMR machinery. Heterodimer MSH (MutS homologs, hMutSα (MSH2-MSH6), hMutSß 
(MSH2-MSH3)) recognizes small insertions. In turn, deletions and mismatched bases and 
the template and non-template DNA strands are determined. Heterodimeric hMutLα 
(MLH1-PMS2), which endonucleolytic activity depends on the PCNA and RFC proteins, 
interacts with MSH to increase the detection of mismatched DNA. MutLα is responsible 
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for the incision 5’ to the mismatch. The excision of damaged DNA is catalyzed by the EXO1 
exonuclease (5’3’ excision), while the DNA polymerase Pol δ drives DNA re-synthesis. 
The incorrect nucleotide and adjacent base pairs are eliminated and replaced by matching 
bases. During this step, single-strand DNA-binding protein RPA plays an important role in 
the termination of DNA excision and stimulation the process of DNA re-synthesis. DNA 
ligase I is responsible for the nick ligation (Li 1999; Stojic, Brun et al. 2004; Kunkel and Erie 
2005; Iyer, Pluciennik et al. 2006; Hsieh and Yamane 2008; Li 2008). Failures in 
appropriate completion of the MMR process caused by gene mutations result in 
predisposition to diseases and serious dysfunctions, i.e. cancers related to the Lynch 
syndrome (mutations in genes: MLH1, MSH2, PMS2), sporadic cancers, resistance to 
chemotherapeutics or sterility in mammals (Modrich and Lahue 1996; Kunkel and Erie 
2005). 
 
1.2.1.2. Role of RINT1 in DNA repair and DNA damage-induced cell 
cycle checkpoints 
RINT1 protein was discovered in the context of irradiation-induced G2/M checkpoint 
control (Xiao, Liu et al. 2001). It was identified by yeast two-hybrid (Y2H) screen of a 
human B-cell cDNA library using a C-terminal fragment of human RAD50 protein as a bait. 
RAD50 is one of the SMC (structural maintenance of chromosomes) protein family 
members, and as component of the MRN complex, participates in DSBs repair (Fig. 8). The 
interaction between RINT1 and RAD50 was detected specifically during late S and G2/M 
phases of the cell cycle. Expression of an N-terminally truncated, dominant negative 
mutant of RINT1, which binds to RAD50, led to delay of G2/M cell cycle checkpoint 
following γ-irradiation. These observations suggested a role of RINT1 in G2/M cell cycle 
checkpoint regulation after DSBs repair (Xiao, Liu et al. 2001). 
 
1.2.1.3. RINT1 and DNA mismatch repair (MMR) 
Recently, RINT1 function has been putatively linked to the Lynch syndrome (LS), a disease 
caused by the mutations in genes encoding proteins of the MMR pathway (Park, Tao et al. 
2014). The exome-sequencing study of multiple case breast cancer family members, 
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detected three rare RINT1 mutant variants (RINT1 c.343C>T (p.Q115X), c.1132_1134del 
(p.M378del), c.1207G>T (p.D403Y)), predisposing their carriers not only to breast cancer, 
but also to the LS, a disease often called hereditary nonpolyposis colorectal cancer 
(HNPCC). LS is hereditary autosomal dominant genetic disease resulting in predisposition 
for colon cancers, but also other cancer types such as stomach and liver cancers, cancer 
of the small intestine, upper urinary tract cancer, cancer of skin, brain and hepatobiliary 
tract. In women, the LS increases probability of ovary and endometrium cancer 
(Kohlmann and Gruber 1993; Park, Tao et al. 2014). LS-affected individuals have a lifetime 
risk for colon cancer of 80%. The prevalence of the LS was estimated to be 1-3% (de la 
Chapelle 2005). At molecular level, the LS is caused by a defective MMR pathway and 
germline defects in mismatch repair genes: MLH1, MSH2, MSH6, PMS2 or EPCAM (Jang 
and Chung ; Peltomaki 2005; Tiwari, Roy et al. 2015). Thus, it is a matter of question, what 
is the role of RINT1 in the MMR pathway and how this gene function could be linked to 
the occurrence of the Lynch syndrome. 
 
1.2.2. RINT1 and ER-Golgi trafficking 
1.2.2.1. Membrane trafficking 
Membrane trafficking, named also vesicle trafficking, refers to the cellular activity by 
which proteins as well as other macromolecules are administered and distributed 
throughout the cell and released to, or incorporated from the extracellular milieu. It is 
thus a core mechanism in cellular biosynthesis, secretion and endocytosis, underpinning 
cell homeostasis. Membrane trafficking processes are inseparably connected with the 
cytoskeleton, cell metabolism, signaling, movement and proliferation (Bonifacino and 
Glick 2004). 
Fundamental structures in membrane trafficking network are endoplasmic reticulum (ER) 
and Golgi apparatus. These are two organelles constitute the major route of vesicular 
transport. Briefly, ER functions as an organelle where the synthesis of proteins and 
membrane lipids takes place. The Golgi is responsible for packaging proteins received 
from the ER into membrane-bound vesicles before their shuttle to the final place of 
destination. Golgi itself consists of compartments forming two networks: the cis Golgi 
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network (CGN), originating from fused cargo-bearing vesicles coming from the ER, and the 
trans Golgi network (TGN), a terminal structure of Golgi, where cargo is bundled up into 
vesicles and transported to the target compartment (Fig. 9). Vesicle transport from the ER 
to Golgi complex is called anterograde transport, while in the opposite direction is named 
retrograde transport (Bonifacino and Glick 2004; Guo, Sirkis et al. 2014; Spang 2015). 
 
 
 
 
 
 
 
 
 
 
Figure 9. Membrane vesicular trafficking in the cell (adapted from Kirchhausen (Kirchhausen 
2000)). 
 
Highly organized and dynamic network of membrane-bounded vesicles mediates the 
intracellular shuttle processes. Transported proteins are associated with vesicle 
membranes or enclosed within them. The transport occurs in a step-wise manner, and 
each step is precisely regulated by the complex molecular machinery controlling sorting 
and burdening of cargo, as well as vesicle movement and unloading of transported 
molecules. Characterization of the proteins required for cargo selection, loading and 
carrier budding, allowed to identify three different types of transporting vesicles: (i) COPI- 
(coat-protein complexes I) coated, (ii) COPII- (coat-protein complexes II) coated and (iii) 
clathrin-coated vesicles (CCVs) (Fig. 9). The COPI- and COPII-coated vesicles participate in 
the secretory pathway (retrograde and anterograde transport) and CCVs are a part of the 
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transport within the endosomal membrane system and mediate endocytosis at the 
plasma membrane. COP-vesicles are made of large protein complexes consisting of seven 
(in case of COPI) or four (in case of COPII) coat-protein subunits and associated small 
GTPases (hydrolase) enzymes, participating in the cargo loading. Clathrin-coated vesicles 
are critical for the process of endocytosis, thus ensure the import of proteins and lipids 
from the extracellular milieu. Clathrin made of polypeptide chains building three-legged 
structures named triskelions aggregates with the help of adaptin protein complex to form 
coated cavities on the surface of a membrane (the vesicular coat) while GTPase separates 
the mature CCV from the membrane (Schekman and Orci 1996; Nickel, Brugger et al. 
2002; Bonifacino and Glick 2004; Saito and Katada 2015). 
Other group of proteins needed for accurate membrane trafficking are NSF (N-
ethylmaleimide-sensitive factor) and SNARE (soluble NSF attachment protein receptor, 
SNAP receptor) proteins, which mediate docking and fusion of transport vesicles with 
their target membrane compartments. The SNAREs could be divided into two classes: 
vesicle or v-SNAREs, incorporated into the membranes of transport vesicles during 
budding process, and target or t-SNAREs, located in the membranes of destination 
compartments (Bonifacino and Glick 2004; Jung, Inamdar et al. 2012; Stow 2013; Meng 
and Wang 2015). 
 
1.2.2.2. RINT1 function in membrane vesicle trafficking and dynamic 
integrity of the Golgi apparatus and centrosome 
 
Valuable information about putative role of RINT1 in membrane vesicle trafficking and 
correct cell cycle progression were provided by the RNA interference (RNAi) experiments 
performed in HeLa cells (Lin, Liu et al. 2007). The experiments demonstrated that 
depletion of RINT1 led to dispersal of Golgi apparatus and loss of its pericentrioliar 
location, with simultaneous centrosome amplification in interphase. Further studies on 
synchronized cells shown that RINT1-depleted cells exhibited various abnormalities upon 
the mitotic entry: missegregation of chromosomes, multiple spindle poles formation and 
abnormal Golgi dynamics during early mitosis as well as incorrect reassembly of Golgi in 
the telophase. As a consequence of faulty mitosis and multiple cellular defects, cells 
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underwent cell death. Concluding, based on the research of Lin and colleagues, RINT1 was 
found to be a protein essential for dynamic integrity maintenance of both centrosome 
and Golgi apparatus. 
Other studies confirmed significance of RINT1 for vesicle trafficking (Fig. 10). Extensive 
binding assays shown that RINT1 interacts with ER-localized t-SNARE, syntaxin 18 (Table 
II), thus it is involved in the regulation of the membrane trafficking between ER and Golgi. 
Together with ZW10, p31 and NAG proteins, RINT1 forms subcomplex which is a 
peripheral membrane component of SNARE, essential for both retrograde and 
anterograde membrane flow (Hirose, Arasaki et al. 2004; Aoki, Ichimura et al. 2009; 
Schmitt 2010). Immunoprecipitation studies demonstrated direct interaction of RINT1 
with the conserved oligomeric Golgi complex (COG) subunit 1 (COG complex subunit 1), 
which is required for appropriate Golgi morphology and function. Thus, in coordination 
with the COG complex, RINT1 regulates SNARE complex assembly at TGN. Interestingly, 
N-terminal ZW10-interaction domain of RINT1 overlaps with COG1 interaction domain of 
RINT1 (Fig. 2), suggesting existence of some kind of “shifting” mechanism.  
Another study on RINT1 and vesicular trafficking uncovered important role of 
ZW10/RINT1 complex in appropriate Rab6-dependent membrane trafficking and 
homeostasis. Rab6 belongs to the family of Rab GTPases, which promotes Golgi-to-ER 
retrograde trafficking (Sun, Shestakova et al. 2007). Participation of RINT1 in endosome-
to-TGN vesicle trafficking was discovered via its interaction with the SNARE domain of 
syntaxin 16 (Sun, Shestakova et al. 2007; Arasaki, Takagi et al. 2013). Not surprisingly, 
RINT1 knock-down in HeLa cells blocked endosome-to-TGN membrane flow and led to 
redistribution of protein markers of TGN (Arasaki, Takagi et al. 2013). Figure 10 
summarizes known interactions of RINT1 with components of the ER and TGN SNAREs, 
while in Table II lists all known RINT1 interactors together with functional significance of 
the given interaction. 
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Figure 10. The interactions of RINT1 with tethers and SNAREs in the TGN and ER (adapted from 
Tagaya et. al. (Tagaya, Arasaki et al. 2014)). SNARE binds the COG complex through RINT1 (left 
panel). RINT1 and NAG bind to N-terminal regions of BNIP1 and Use1/p31, respectively (right 
panel). N and C represent N- and C-terminal regions of the protein. Numbers 1-8 indicate subunits 
of COG (Cog1 – Cog8) organized in three heterodimeric subcomplexes. Dashed lines indicate 
connections between proteins/SNAREs. 
 
 
Table II. RINT1 interaction partners and functions of the interactions. 
Name of RINT1 partner Function of the interaction 
BNIP/SEC20L ER-Golgi trafficking (Nakajima, Hirose et al. 2004) 
COG complex subunit 1 vesicle trafficking (Arasaki, Takagi et al. 2013) 
UVRAG 
positive regulator of the ER-tether in Golgi-ER retrograde 
transport, cis-Golgi maintenance (He, Ni et al. 2013) 
p130 (RBL2, 
retinoblastoma-like 2) 
telomerase-independent telomere length maintenance 
(Kong, Meloni et al. 2006) 
RAD50 
irradiation-induced G2/M cell cycle checkpoint regulation 
(Xiao, Liu et al. 2001) 
syntaxin 16 (STX16) endosome-to-TGN trafficking (Arasaki, Takagi et al. 2013) 
syntaxin 18 (STX18) 
ER-Golgi trafficking (Hirose, Arasaki et al. 2004; Aoki, 
Ichimura et al. 2009; Civril, Wehenkel et al. 2010) 
ZW10 
ER-Golgi trafficking (Hirose, Arasaki et al. 2004; Arasaki, 
Taniguchi et al. 2006) 
Introduction 
 
20 
 
1.2.3. Oncogenic and tumor suppressor functions 
1.2.3.1. Oncogenes and tumor suppressor genes 
Oncogenes and tumor supressor genes are the key players in cancer development. Both 
classes of genes encode proteins involved in cell growth control and proliferation. 
The oncogenes are derived from proto-oncogenes, which code for proteins enhancing cell 
growth and division, controlling cell cycle progression or proteins inhibiting cell death. 
Thus, products of oncogenes are aberrant versions of proteins normally involved in 
molecular signal transduction cascades mediating growth, proliferation or pro-survival 
signals, such as membrane receptors, proteins transporting the signal across the 
cytoplasm, and finally, transcription factors in the nucleus activating e.g. genes 
responsible for cellular division. Importantly, oncogenic versions of proteins, being 
dominant, tend to activate signaling pathways unceasingly, resulting in excessive 
production of cell growth stimulators, thus contributing to development of cancer.  
Alteration from an oncogene to the proto-oncogene might be a result of mutation. It 
could also be a consequence of chromosomal rearrangement changing genomic location 
of the proto-oncogene (e.g. a novel location results in strong transcription of proto-
oncogene due to hyper-activated gene promoter of novel gene locus or in fusion with 
other highly expressed protein, e.g. BCR-Abl). A shift from proto-oncogene to oncogene 
could also be caused by an increase in number of gene copies (e.g. duplication). In 
addition, conversion from proto-oncogene to an oncogene could be an effect of infection 
and resulting insertions of viral DNA disrupting correct genomic architecture of proto-
oncogene. 
All of these processes result in gain-of-function mutations. Moreover, since most of the 
oncogenes carry dominant mutations, only single copy of mutated proto-oncogene may 
result in cancerous transformation. If such mutation occurs in germ line cells, offspring 
will acquire predisposition to tumor formation.  
Exemplary proto-oncogene is c-Myc gene, which encodes a transcription factor and 
controls expression of plethora of genes involved in cellular growth, proliferation and 
differentiation. Mutations in this gene transforms it to an oncogene associated with most 
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forms of cancers. Another example of proto-oncogene is Ras, which, if mutated, causes 
unrestrained cell growth. Products of Ras gene are involved in kinase signaling pathways 
controlling gene transcription and regulating cell growth and differentiation. Another 
oncogene is Src, the first oncogene described. It encodes a tyrosine kinase, regulating 
cellular growth, differentiation and motility. 
Moreover, viruses may carry their own oncogenes, which are transduced to infected cells. 
These include: Tax protein deregulating cell cycle and encoded by human T-lymphotropic 
virus (HTVL), E6 and E7 proteins inactivating tumor supressor proteins p53 and pRb, 
respectively, carried by human papilloma viruses (HPV16 or HPV18), or v-FLIP protein 
inhibiting pro-apoptotic proteins caspase 8 and 10 and encoded by human herpesvirus 8 
(HHV-8). 
Tumor suppressor gene, or anti-oncogene, usually encodes protein inhibiting cell 
proliferation or leading to cellular death, and therefore naturally preventing tumor 
growth. When mutated and lacking their original function, tumor suppressor genes lead 
to deregulation of cell growth and proliferation processes. Mutations are usually 
recessive, meaning that both copies of a gene are mutated, and lead to a loss-of-function. 
An example of the disease caused by mutated tumor suppressor gene, is  retinoblastoma, 
a tumor developing in early childhood due to dysfunction of Rb gene (Giacinti and 
Giordano 2006). Other example is familial adenomatous polyposis of the colon (FAP), 
generated by mutations of APC gene, which product controls the availability of 
transcription factor ß-catenin (Ficari, Cama et al. 2000). Hereditary breast cancer results 
from mutations of BRCA2 tumor suppressor gene, and hereditary breast and ovarian 
cancer is related to mutations in BRCA1 gene (Lee and Muller 2010). Another important 
tumor suppressor gene is TP53, encoding transcription factor p53 regulating cell division 
and cell death. Its mutation is related with cancers of colon, breast and lung. Moreover, 
modified p53 protein is involved in leukemias, lymphomas, sarcomas, and neurogenic 
tumors (Royds and Iacopetta 2006; Olivier, Hollstein et al. 2010). 
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1.2.3.2. Oncogenic and tumor suppressor function of RINT1 
In line with extensive function of RINT1 in controlling the ER-Golgi homeostasis, RINT1-
depleted cells exhibited abnormalities in Golgi dynamics and integrity as well as improper 
functioning of centrosome during cell division (Arasaki, Taniguchi et al. 2006; Lin, Liu et al. 
2007; Arasaki, Takagi et al. 2013). Such observations suggest tumor suppressor function 
of RINT1. The tumor suppressor role was confirmed by the study demonstrating that 
Rint1 is involved in the tumor development in mice. Inactivation and heterozygous loss of 
Rint1 led to tumor formation in about 81% of knock-out mice. Interestingly, homozygous 
deletion of Rint1 caused early embryonic lethality and the failure of blastocyst outgrowth 
ex vivo (Lin, Liu et al. 2007). Another, recently published data revealed, that RINT1 could 
be a gene predisposing to breast cancer. Multiple-case, breast cancer family whole exome 
sequencing analysis, showed that rare RINT1 sequence variants may lead to the 
development of breast cancer and to Lynch syndrome-spectrum cancers (Park, Tao et al. 
2014). Since another known function of RINT1 is telomerase-independent telomere 
length maintenance realized by RINT1 interaction with Rb-related, p130 protein (Kong, 
Meloni et al. 2006), a RINT1 mutation could potentially lead to decreased chromosomal 
stability, and thus contribute to tumorigenesis. 
However, there are also studies showing that RINT1 is a cancer-promoting gene. The gain- 
and loss-of-function screens identified RINT1 as a novel oncogene in glioblastoma 
(Quayle, Chheda et al. 2012). Other research results demonstrated that high expression of 
RINT1 in low-grade glioma patients was associated with higher risk of epileptic seizure 
occurrence (Fan, Wang et al. 2014). 
Figure 11 summarizes cellular processes involving RINT1 and regulatory interactions 
described until now. 
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Figure. 11. Cellular processes involving RINT1 and their cellular localization together with 
respective interaction partners. 
 
1.3. General mechanisms regulating protein functions 
In order to provide and control accurate functioning of the cell, proteins need to be 
precisely regulated. The protein regulatory mechanisms could be divided into several 
groups: transcriptional and translational control, processes modifying spatial localization 
of the proteins, covalent or non-covalent interactions with effector molecules, control of 
the quantity and lifetime of active proteins and control of protein activity due to changes 
of intracellular pH and redox environment. A single protein may be subjected to various 
regulatory operations (Perutz 1989; Goodsell 1991; Jensen and Shapiro 2000; Kornitzer 
and Ciechanover 2000). 
Significant category of mechanisms influencing protein function are post-translational 
protein modifications (PTMs). They are fundamental and powerful biochemical tool 
influencing whole proteome, thereby having an impact on various aspects of cell biology, 
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(i.e. modification of tubulin leads to diversity in microtubules, which differ depending on 
the cellular developmental stage, cell compartment, or the cell cycle stage (Song and 
Brady 2015)). By modulating protein activity, localization, fate, and interaction with other 
molecules, PTMs increase functional diversity of proteins. Sometimes reversible and very 
often enzyme-mediated (e.g. ligases, phosphatases, kinases), PTMs are executed by: (i) 
the covalent addition of functional groups or specific molecules to the proteins, (ii) by the 
cleavage of different regulatory subunits or (iii) by the degradation of the proteins. 
Ubiquitination, phosphorylation, methylation, acetylation, SUMOylation and 
glycosylation, are among the most ubiquitous and important PTMs (Hunter 2007; 
McDowell and Philpott 2013). 
Importantly, precise mechanisms controlling cellular functions of RINT1 are not yet 
known or described. Foremost, there was no functional data available regarding RINT1 
PTMs until now. 
 
1.3.1. Regulation of protein lifetime 
One of the ways to regulate protein function is to control its lifetime. Half-life of a protein 
may vary from few minutes to many days, depending on the stability of protein structure 
and on the cellular mechanisms and rates of the degradation. Proteins of the shortest 
half-life are generally significant for crucial cellular processes, therefore, usually involved 
in the regulation of cell growth and proliferation or catalyzing important steps in 
metabolic signaling. Fast adjustment of the concentration of a gene product, allows for 
rapid response to environmental changes and provides cellular homeostasis 
(Hochstrasser 1995; Toyama and Hetzer 2013). Moreover, selective protein degradation 
regulates the relative timing of molecular events in the cell (Liu, Urbe et al. 2012) and is 
indispensable for removing proteins that are no longer needed, even if still functional. 
Another important function of protein lifetime regulation is to eliminate damaged and 
potentially harmful proteins. Once misfolded or subjected to abnormal PTM, protein may 
become toxic and unwanted component of the cell and cause, so called “protein 
deposition diseases”, such as Alzheimer’s disease, Huntington’s disease (HD), Parkinson’s 
disease, Amyotrophic Lateral Sclerosis (ALS) or spongiform encephalopathies (Kaytor and 
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Warren 1999; Bucciantini, Giannoni et al. 2002; Goldberg 2003; Haynes, Titus et al. 2004; 
Ciechanover and Kwon 2015). 
One of the characteristics of the intracellular protein degradation, is its dependence on 
the cellular energetic status (ATP pool). Another important feature is its processiveness; 
meaning, that if a protein is selected for the degradation, it is completely degraded to 
small peptides and no intermediate larger fragments are produced (Ciechanover 2005). 
In eukaryotic cells proteasomal degradation pathway and lysosomal degradation pathway 
constitute major mechanisms leading to protein degradation. 
 
1.3.1.1. Proteasomal degradation of proteins 
Proteasomal degradation or the ubiquitin-proteasome system, is the major pathway of 
protein degradation. It is thought to occur in both the nucleus and the cytoplasm (Floyd, 
Trausch-Azar et al. 2001; von Mikecz, Chen et al. 2008). Nevertheless, recent studies 
question the possibility of nuclear proteasomal degradation (Chen and Madura 2014). In 
order to be subjected to proteasomal degradation, protein has to be covalently modified 
by a chain of ubiquitin polypeptide at  first (Fig. 14). Then, tagged for the degradation by 
polyubiquitination, a target protein binds to the 26S proteasome, situated in the 
cytoplasm (Fig. 12). 26S proteasome is a highly specialized and very large (~2.5 MDa) 
ubiquitin-dependent protease, that consists of at least 32 different polypeptides, forming 
a complex (Fig. 14). 
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Fig. 12. Schematic subunit composition of the 26S proteasome and proteasomal protein 
degradation. 20S catalytic core complex and two 19S regulatory complexes constitute the 26S 
proteasome (left panel). The proteasome recognizes Ub-tagged protein and initiates degradation 
at a relaxed region of the substrate. The protein is translocated through the degradation channel, 
cleaved into peptides and finally released (right panel). 
 
Prior to proteolysis within the 26S proteasome, polyubiquitin chain tag has to be removed 
from the substrate by deubiquitinating enzymes, located in the 19S regulatory 
subcomplexes (or caps) of the proteasome (Fig. 14). Moreover, these parts of the 
protease contain ATPase subunits that use the energy of ATP hydrolysis to perform 
unfolding of the protein. Such processed protein is subsequently translocated to the core 
of 26S proteasome, a central 20S subcomplex forming a hydrolytic chamber, where 
processive proteolysis takes place. As a consequence, small peptides of ~8 to 12 amino 
acids are generated and released from the proteasome. 
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1.3.1.2. Non-proteasomal degradation of proteins 
1.3.1.2.1. Lysosomal proteolysis 
Protein degradation may also occur in lysosomes, which are membrane-enclosed 
organelles, containing a variety of hydrolytic proteases. Proteins that are to be degraded 
by this mechanism are shifted to lysosomes and subjected to the intra-lysosomal 
proteolysis. In particular, selective proteolysis of the cytosolic substrates is fulfilled by the 
recognition of the dedicated peptide sequence (related to the sequence Lys-Phe-Glu-Arg-
Gln) on a given protein, which results in subsequent sorting towards lysosome. Another 
particular feature of the lysosomal degradation is conferred by the regulatory function of 
intra-lysosomal pH, i.e. lysosomal proteases of cathepsin family are active only under 
highly acidic pH conditions of the lysosome (pH 4.8) (Ciechanover 2005; Schulze, Kolter et 
al. 2009; Appelqvist, Waster et al. 2013). 
 
1.3.1.2.2. Autophagy 
Generally, autophagy is a cellular mechanism to degrade random cytoplasmic proteins 
under stressful conditions, e.g. during starvation. In such unselective mode autophagy 
can also play a role in programmed cell death. However, in its selective mode autophagy 
contributes to repair of damaged organelles (e.g. mitophagy - selective digestion of 
damaged mitochondria) or could be strictly linked with the lysosomal pathway of protein 
degradation. Selective autophagy is a complex process, based on cargo-specific 
autophagy receptors and tightly regulated on a molecular level. 
Autophagy involves enclosing organelles and cytosol within double-membrane structures, 
which are subsequently degraded by the lysosome. The whole process starts with the 
formation of a transient pre-autophagosome (PAS). Next, two-lipid bilayers-surrounded 
organelle, the autophagosome (Fig. 13) is formed, which insulates the cytoplasmic 
structures that are to be degraded. Subsequently, outer membrane of autophagosome is 
fused with lysosome, creating a membranous vesicle within lysosome. This structure, 
called an autophagic body, is decomposed and its interior digested by lysosomal enzymes 
(Noda, Suzuki et al. 2002; Klionsky 2007; Levine, Mizushima et al. 2011).  
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Over 30 genes and their products have been identified as autophagy-related (Atg) and 
classified into one of the following groups: (i) ULK1 kinase complex, responsible for the 
autophagy induction, (ii) Atg9, involved in the recycling of the membrane, (iii) PI3K 
complex I (including beclin 1), which drives autophagosome formation (isolation of 
membrane nucleation, elongation and completion) (iv) PI(3)P-binding ATG2-ATG18 
complex, (v) ubiquitin-like protein conjugation system ATG5-ATG12/ATG16L1, essential 
for the pre-autophagosome creation, and (vi) ubiquitin-like protein conjugation system 
LC3-PE (LC3-phosphatidylethanolamine), playing a role in membrane expansion. The ULK1 
complex is negatively regulated by a mammalian Target of rapamycin complex 1 
(mTORC1) kinase (Pyo, Nah et al. 2012; Boya, Reggiori et al. 2013).  
 
 
 
 
 
 
 
 
 
 
Figure. 13. Schematic representation of autophagy process. First, the cellular component 
subjected to autophagy is being isolated by a double-membrane autophagosome. Next, the whole 
structure fuses with lysosome and forms an autophagic body. Finally, the content of a vesicle is 
degraded. 
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1.3.2. Ubiquitination and its biological significance 
Ubiquitination, also known as ubiquitylation, is a versatile enzymatic reaction, in which 
ubiquitin (Ub) molecules are covalently attached to lysine residue on substrate proteins 
or itself, at one or multiple sites. This post-translational modification directs eukaryotic 
proteins to miscellaneous fates, and is considered to be spatial-, temporal- and substrate-
specific. Ubiquitin is a small, 8-kDa polypeptide that consists of 76 amino acids and is 
highly evolutionary conserved. In humans, Ub is a product of four genes: UBB, UBC, 
UBA52 and RPS27A. UBB and UBC genes code for a linear ubiquitin chain precursor 
consisting of at least four Ub molecules. Two other genes, UBA52 and RPS27A, encode a 
single copy of Ub fused to the ribosomal proteins L40 and S27a, respectively.  In order to 
ensure functionality, the UBB- or UBC-encoded Ub precursor is processed by 
deubiquitinating enzymes (ubiquitin proteases) and cleaved to monomers. 
As it is shown in Figure 14, ubiquitin has seven internal lysines (Lys, K) used during 
polyubiquitin chain formation, and C-terminal diglycine motif (GG) serving for attachment 
to ubiquitinated substrate (Peng, Schwartz et al. 2003; Kimura and Tanaka 2010; 
Komander and Rape 2012). 
 
 
 
 
Figure 14 Schematic representation of ubiquitin molecule and positions of internal ubiquitin 
lysines. K = lysine, GG = diglycine. 
 
1.3.2.1. Process of ubiquitination  
The process of attaching ubiquitin to the substrate is mediated by the sequential action of 
three classes of enzymes: ubiquitin-activating enzymes (E1s), ubiquitin-conjugating 
enzymes (E2s, also known as UBCs or ubiquitin carrier proteins) and ubiquitin-protein 
ligases (E3s) (Pickart 2001; Ye and Rape 2009). At first, C-terminal carboxyl group of Ub 
forms a thioester linkage with the active site of the cysteine of E1, and therefore activates 
 
        GG K K K K K K K 
6 11 27 29 33 48 63 
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Ub. This step is energy-dependent and requires Adenosine-5’-triphosphate (ATP). Then, 
Ub is transferred (trans-thiolated) from the E1 to the catalytic cysteine of one of around 
40 E2s. This conjugate associates with the third enzyme of the cascade, E3 ubiquitin 
ligase, to finally transfer Ub from E2 to the Ɛ-amino group of target protein lysine (Fig. 
15). 
 
 
 
 
 
 
 
 
 
 
Figure 15. Schematic representation of ubiquitination process. Attachment of ubiquitin to the 
substrate lysine is executed by the cascade activity of three enzymes: ubiquitin-activating enzyme 
(E1), ubiquitin-conjugating enzyme (E2) and ubiquitin ligase (E3). The protein recognition by E3 
ligase assures the specificity of reaction. 
 
Initial attachment of a single Ub molecule to its target, called monoubiquitination, is 
usually, but not always, followed by the attachment of another Ub molecule(s). In this 
case, lysine of the Ub already conjugated with the substrate serves as an acceptor for the 
next Ub(s). Ubiquitin conjugation is a reversible process through the activities of 
proteases, called deubiquitinases or deubiquitinating enzymes (DUBs), which are able to 
cleave off the single Ub molecule or Ub polychain. DUBs have several functions in the 
ubiquitination pathway. They remove single molecule or polyUb chain from the target, 
thus serve as antagonists for the ubiquitination process. They also activate polyUb 
precursor by the proteolysis and recycle the pool of monoUb in the cell by the cleavage of 
free polyUb chains. Some DUBs are able to cleave ubiquitin-like proteins such as SUMO.  
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1.3.2.2. E3 and E4 ubiquitin ligases 
E3 ubiquitin ligases are enzymes that enable binding of Ub to the substrate. They also 
confer the specificity of ubiquitination by recognizing a specific protein target. For 
example, they are the factors which provide the specificity to proteasomal degradation by 
recognizing and ubiquitinating the proteins subsequently degraded. Currently, there is 
more than 600 E3s described, that belong to the one of two major families of E3 ubiquitin 
ligases, which are: the Really Interesting New Gene (RING) family, and the Homologous to 
E6-AP Carboxyl Terminus (HECT) family (Tab. 3.). These two groups of ligases catalyze 
ubiquitination reaction in a different manner. RING domain E3 ligases bind both the 
E2~Ub conjugate and the substrate protein and lead to the direct transfer of C-terminal 
diglycine of Ub to a substrate lysine, and therefore allow formation of an isopeptide 
bond, and as a consequence, ubiquitination.  
 
Table III. Comparison between RING domain and HECT domain family of E3 ubiquitin 
ligases. 
 RING family HECT family 
number of 
members 
~600 ~30 
characteristics RING finger is Zn2+-coordinating 
domain; consists of a series of 
cysteine and histidine residues; 
does not form a catalytic 
intermediate with Ub; function 
as monomers, dimers or multi-
subunit complexes 
HECT domain consists of 
~350 aa, is located at the C-
terminus; N-terminal 
domain serve for targeting a 
substrate 
main functions cell cycle progression, apoptosis, 
proteasomal degradation of the 
proteins, angiogenesis (Metzger, 
Hristova et al. 2012) 
protein trafficking, immune 
response, signaling 
pathways regulating cellular 
growth and proliferation 
(Rotin and Kumar 2009) 
examples MDM2 (regulates p53), IAPs, 
APC/C family, SCF family, CBL 
family 
UBE3A (E6AP), NEDD4 family 
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The RING finger domain serves as a scaffold bringing E2 and the target protein together. 
Members of the HECT E3 Ub ligases first bind Ub from the E2~Ub complex onto catalytic 
cysteine and form thioester intermediate with the catalytic cysteine, and then transfer it 
to the target protein (Deshaies and Joazeiro 2009; Metzger, Hristova et al. 2012; 
Sadowski, Suryadinata et al. 2012; Berndsen and Wolberger 2014). 
LUBAC (Linear Ubiquitin Chain Assembly Complex) is a special E3 ubiquitin ligase, which 
catalyzes formation of linear ubiquitin-chains. In humans, it is known to consist of HOIL-1 
(RBCK1), HOIP (RNF31) and SHARPIN and has a MW of approximately 600 kDa, probably 
due to the hetero-multimeric assembly of a complex. Although, as a separate protein, 
HOIL-1 was previously described as an ubiquitin ligase, in the case of LUBAC complex the 
HOIP protein is responsible for the E3 ligase activity of LUBAC. As for now, LUBAC is one 
of the two E3 ligases known to participate in the head-to-tail ubiquitin chain formation 
(Haas, Emmerich et al. 2009; Emmerich, Schmukle et al. 2011; Ikeda, Deribe et al. 2011; 
Tokunaga and Iwai 2012; Rieser, Cordier et al. 2013). Another E3 ubiquitin ligase recently 
suggested to mediate linear connection of the ubiquitin molecules is Parkin (Muller-
Rischart, Pilsl et al. 2013). Table IV briefly describes E3 ubiquitin ligases found as RINT1 
modulators in the course of the experimental part of presented work. 
 
Table IV. E3 ubiquitin ligases found as interacting partners of RINT1. 
E3 ubiquitin 
ligase 
Alternative names Biological processes involving 
ligase activity 
HUWE1 MULE, LASU1, 
UREB1, ARF-BP1, 
HSPC272, HECTH9, 
URE-B1 
base-excision repair (Parsons, Tait et al. 
2009), histone ubiquitination (Liu, Oughtred 
et al. 2005), protein mono- (Parsons, Tait et 
al. 2009) and polyubiquitination (Zhong, 
Gao et al. 2005) 
RNF20 BRE1, BRE1A histone H2B ubiquitination (Zhu, Zheng et 
al. 2005), histone monoubiquitination (Kim, 
Hake et al. 2005), regulation of cell 
migration (Shema, Tirosh et al. 2008), 
regulation of transcription (Pavri, Zhu et al. 
2006; Shema, Tirosh et al. 2008), protein 
polyubiquitination (Liu, Oh et al. 2009), 
regulation of mRNA polyadenylation 
(Pirngruber, Shchebet et al. 2009) 
RNF40 BRE1B, RBP95, 
STARING 
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It should be noted, that ubiquitination may also occur in E3 ligase-independent manner. 
Such modification is possible through direct and non-covalent interaction between Ub 
molecule and ubiquitin-binding domain of a substrate (UBD) (Hoeller, Hecker et al. 2007). 
Currently, there are more than twenty UBDs described, which exhibit preference for the 
specific Ub chains, i.e. depending on the length of Ub chains or inter-ubiquitin linkage 
type. The interplay between Ub and UBD plays an important role in such processes as 
proteolysis (e.g. α-helix UIM domain of proteasome subunit S5a), endocytosis (e.g. SH3 
domain of CIN85 protein) or in DNA repair (e.g. zinc finger UBZ domain of polymerase-h) 
(Bienko, Green et al. 2005; Wang, Young et al. 2005; Stamenova, French et al. 2007; Dikic, 
Wakatsuki et al. 2009). 
 
The nomenclature of enzymes involved in the ubiquitination process includes additional 
group of ligases, named E4 ubiquitin ligases or ubiquitin chain assembly factors. They 
serve as the enhancers of E3 ligase-mediated transfer of Ub to a protein target, thus are 
involved in multiubiquitin chain assembly and facilitate polyubiquitination. Examples of 
E4 enzymes are UFD2 in yeast and its human homolog UBE4B (Wu and Leng 2011; Micel, 
Tentler et al. 2013). 
 
1.3.2.3. Types of ubiquitination 
There are two major types of ubiquitination depending on nomenclature: (i) number of 
target lysines (K), which are ubiquitinated, (ii) number of molecules of Ub attached to the 
substrate. If a protein is subjected to ubiquitination on a single lysine, this process is 
called monoubiquitination; if several lysines of the substrate are involved, it is 
multiubiquitinated. Nevertheless, monoubiquitination occurs also when Ub is attached to 
the target protein as a monomer. Conversely, successive addition of another Ub(s) results 
in polyubiquitination. Alternative mode of inter-ubiquitin linkage that does not involve Ub 
lysine, results in linear, so-called “head-to-tale” ubiquitin chain formation (see also 
1.2.1.4.). Some examples of different ubiquitination types are shown in Figure 16. 
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Figure 16. Nomenclature of ubiquitination depending on the ubiquitin chain typology and 
number of targeted lysine residues. 
 
In the canonical ubiquitination process, substrate protein is modified by a covalent 
linkage of Ub to the amine group of lysine residue of the target protein. Recently, some 
new modes of ubiquitin chain attachment have been described. It was reported, that Ub 
may covalently modify its substrate and bind to non-lysine site of the protein, such as N-
terminal amine group, the hydroxyl group of serine and threonine residues (Wang, Herr 
et al. 2007), or the thiol groups of cysteine residues (Cadwell and Coscoy 2005; Williams, 
van den Berg et al. 2007). 
 
1.3.2.4. Ubiquitin chain typologies 
Ubiquitin chains vary in structure, which translates to the function of ubiquitination. Since 
there are seven lysine residues in the Ub molecule, each of them might be potentially 
used to form the polyubiquitin chain (Hochstrasser 2006). Based on homo-/heterogeneity 
of the Ub lysines serving as an inter-Ub linkage, one can distinguish homotypic or mixed 
chains, respectively (Fig. 17). The last ones are branched structures, generated by specific 
RING E3 Ub ligases. Moreover, the α-amino group of the N-terminal methionine (M) 
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residue of Ub can generate the eighth linkage type, which is linear and called “head-to-
tail” or “M1” linkage (Fig. 16) (Kirisako, Kamei et al. 2006; Emmerich, Schmukle et al. 
2011; Walczak, Iwai et al. 2012). In addition, heterologous chains might be formed, if 
post-translational protein modification involves not only Ub, but also e.g. SUMO2 
molecule. 
 
 
 
 
 
 
 
 
 
Figure 17. Ubiquitin-chains typology. Adapted from (Ikeda and Dikic 2008). 
 
1.3.2.5. Functions of ubiquitination 
Although ubiquitination was originally described and is best known as a mechanism 
targeting proteins for degradation by the 26S proteasome (Chau, Tobias et al. 1989; 
Hershko and Ciechanover 1998), it is currently known, that it is also crucial for a variety of 
other cellular processes, e.g. autophagic and lysosomal protein degradation, modulation 
of protein-protein interactions, DNA repair, gene transcription, alteration of subcellular 
localization and distribution, cell cycle regulation or cellular signaling (Passmore and 
Barford 2004; Pickart and Eddins 2004; Hunter 2007; Clague and Urbe 2010; Mocciaro 
and Rape 2012). Such wide range of ubiquitination functions is specified by the inter-
ubiquitin chain typologies, i.e. the role of ubiquitination and fate of the protein substrate 
largely depend on which lysine residue of Ub serves as an inter-ubiquitin chain linker. Of 
course, other factors influencing ubiquitination are Ub receptors and deubiquitinating 
enzymes (DUBs) (see 1.3.2.1. and 1.3.2.2.). The most characterized mode of 
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ubiquitination, is K48-mediated polyubiquitination (Ub K48), where at least four Ub 
molecules are linked one to another via lysine residue on position 48. Its main role is to 
regulate cellular protein levels by targeting them for the proteasomal degradation 
(Hershko and Ciechanover 1998). Other, relatively well-described type of ubiquitination, 
is K63-mediated polyubiquitination (Ub K63). These poly-Ub chains are mostly associated 
with non-degradative functions, such as lysosomal protein sorting, signal transduction, 
DNA damage or endocytosis (Passmore and Barford 2004; Mukhopadhyay and Riezman 
2007; Chiu, Zhao et al. 2009; Lauwers, Jacob et al. 2009; Yang, Zhang et al. 2010), but 
recent studies show that they might also serve as a tag for degradation. Different types of 
ubiquitination linked to known functions are presented in Table V. Currently, the exact 
functions of the different types of ubiquitination remain a subject of intensive research. 
 
Table V. Ubiquitination types and their functions. 
Type of ubiquitination Examples of ubiquitination function 
polyubiquitination: K6 linkage regulation of microtubule stability and mitotic 
spindle orientation by α-tubulin ubiquitination 
mediated by MGRN1 ligase 
polyubiquitination: K11 linkage proteasomal degradation, e.g. the anaphase-
promoting complex (APC/C) triggers degradation 
of its mitotic substrate Cyclin B1 by assembling 
K11-linked Ub chains 
polyubiquitination: K27 linkage monoubiquitination of histone H2A, important 
in mitochondrial and T cells biology, e.g. E3 
ligase Parkin catalyzes K27-linked Ub chains on 
voltage-dependent anion-selective channel 
protein 1 (VDAC1), which leads to mitophagy 
polyubiquitination: K29 linkage protein degradation, e.g. lysosomal degradation 
of Deltex (DTX) protein mediated by ITCH/AIP4 
polyubiquitination: K33 linkage important in T cell antigen receptor (TCR) 
signaling, i.e. K33-linked polyubiquitination of ζ-
chain of TCR catalyzed by ITCH leads to the 
reduction of TCR phosphorylation and, as a 
consequence, lessens TCR signaling 
polyubiquitination: K48 linkage 
(at least 4 Ubs) 
generaly proteasomal degradation, e.g. of 
protein MDC1, a key component of DDR 
followed by DSB repair; lysosomal degradation, 
e.g. of LDL receptor 
polyubiquitination: K63 linkage kinase activation and localization (e.g. K63-
linked ubiquitination of transforming growth 
factor-ß activating kinase 1 (TAK1) triggered by 
TRAF6 and indispensable for TAK1 auto-
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phosphorylation), DNA damage tolerance, signal 
transduction, endocytosis (e.g. Epsin1-mediated 
endocytosis of MHCI; TNFα-mediated NF-κB 
activation), lysosomal degradation (e.g. of LDL 
receptor) 
monoubiquitination transcriptional silencing and X-inactivation, i.e. 
as a consequence of monoubiquitination of 
histone H2A; viral budding, gene expression, 
DNA repair, e.g. monoubiquitination of FANCD2 
in response to DNA damage, triggering the 
recruitment of repair proteins to the damaged 
site 
multiubiquitination or 
monoubiquitination on multiple sites 
receptor endocytosis, e.g. multiple 
monoubiquitination of receptor tyrosine kinases 
(RTKs) leads for their endocytosis and 
degradation 
linear (M1) ubiquitination NFκB signaling, i.e. linear ubiquitination of 
NEMO is necessary for NFκB activation; protein 
degradation, i.e. in vitro degradation of Ub-GFP 
 
The table was based on following publications: (Thrower, Hoffman et al. 2000; Hicke 2001; 
Sarcevic, Mawson et al. 2002; Haglund, Di Fiore et al. 2003; Haglund, Sigismund et al. 2003; 
Passmore and Barford 2004; Ben-Saadon, Zaaroor et al. 2006; Chastagner, Israel et al. 2006; 
Kirisako, Kamei et al. 2006; Jin, Williamson et al. 2008; Shi, Ma et al. 2008; Bergink and Jentsch 
2009; Tokunaga, Sakata et al. 2009; Yang, Zhang et al. 2010; Kulathu and Komander 2012; Zhang, 
Xu et al. 2013; Longerich, Kwon et al. 2014; Srivastava and Chakrabarti 2014; Luo, Zhou et al. 
2015) 
 
1.3.3. SUMOylation and SUMO protein 
SUMOylation is a post-translational modification of the proteins mediated by members of 
the Small Ubiquitin-related Modifier (SUMO) protein family and resulting in a covalent 
attachment of a SUMO family member to a target protein. In vertebrates, four SUMO 
isoforms encoded by distinct genes have been identified: SUMO1, SUMO2, SUMO3 and 
SUMO4. Moreover, SUMO2 and SUMO3 proteins share 97% of similarity, thereby are 
specified as SUMO2/3 (Hay 2005; Henley, Craig et al. 2014). Theoretical weight of SUMO 
family members is 10-11 kDa, however, it should be noted that on SDS-PAGE gel SUMO is 
detectable as a 15-17 kDa protein (Park-Sarge and Sarge 2009). As it is the case with 
ubiquitination, SUMOylation as a process is reversible through proteases, such as 
ubiquitin-like protein-specific proteases (Ulps) and sentrin-specific proteases (SENPs) that 
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remove SUMO molecule(s) from SUMO-modified proteins (Johnson 2004). Mature SUMO, 
processed from the precursor form by proteases, is generated when at least four C-
terminal amino acids have been cut off. Such SUMO possesses a carboxy-terminal 
diglycine motif, necessary to form an isopeptide bond with an acceptor lysine residue on 
the substrate.  
SUMOylation regulates and alters a variety of cellular processes, such as transcription 
(e.g. modification of DEC1 protein modifies its transcriptional activity), protein-protein 
interactions and localization (e.g. SUMOylation of the von Hippel-Lindau (VHL) tumor 
suppressor protein leads to its nuclear redistribution), ER stress response and activation 
of unfolded protein response (UPR) (e.g. regulation of PML function), cell cycle 
progression (e.g. modification of Forkhead box transcription factor M1 (FoxM1) 
modulates its transcriptional activity), DNA damage response (e.g. SUMOylation of PCNA) 
and chromosome segregation (Mahajan, Delphin et al. 1997; Kretz-Remy and Tanguay 
1999; Huang, Wuerzberger-Davis et al. 2003; Girdwood, Tatham et al. 2004; Li, Evdokimov 
et al. 2004; Liang, Melchior et al. 2004; Besnault-Mascard, Leprince et al. 2005; Cai and 
Robertson 2010; Hong, Xing et al. 2011; Schimmel, Eifler et al. 2014; Enserink 2015).  
 
1.3.3.1. SUMOylation process 
SUMO conjugation occurs in analogous manner to ubiquitination. Covalent attachment of 
SUMO protein to the acceptor lysine of substrate involves a cascade of enzymes acting in 
particular sequence; first, activating enzymes (E1s), then conjugating enzymes (E2), and 
protein ligases (E3) at the end. At the beginning of the SUMO conjugation cycle, SUMO 
protein undergoes processing by proteases to its mature form. Following maturation, E1 
activating enzyme adenylates C-terminal diglycine of SUMO that subsequently forms an 
E1~SUMO thioester with E1 conserved cysteine residue. Next, SUMO is transferred to the 
active site of conjugating enzyme E2, generating an E2~SUMO thioester. In the last step of 
the process, SUMO E3 ligase might catalyze reaction in two distinct manners. It either 
recruits both E2~SUMO thioester and the substrate into a complex, to allow an optimal 
conformation and to facilitate conjugation, or binds to the E2~SUMO thioester to 
orientate it and to facilitate E2-dependent substrate interaction and binding SUMO to the 
target protein. Second mechanism does not require direct interaction between E3 ligase 
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and the substrate. In both cases, as a result an isopeptide bond between the C-terminal 
carboxyl group of SUMO and the Ɛ-amino group of a lysine residue of the substrate is 
formed. E3 ligase function in SUMO conjugation pathway might be also omitted. In some 
cases, E2 conjugating enzyme interacts directly with SUMO substrate in an E3 ligase-
independent manner, to transfer the cargo directly to acceptor lysines (Gareau and Lima 
2010). Unlike ubiquitination-involved enzymes, only few have been identified in the 
SUMO pathway (Tab. VI), and among them, merely single E2 enzyme in human, which is 
SUMO-conjugating enzyme 9 (UBC9, UBCE9, UBE2I) (Geiss-Friedlander and Melchior 
2007; Zhao 2007; Wilson and Heaton 2008; Yang and Chiang 2013). 
 
Table VI. Examples of E1 and E3 enzymes involved in the SUMOylation. 
E1 activating enzyme Function 
SAE1 (UBLE1A) E1 ligase for SUMO1, SUMO2, SUMO3,  
and probably SUMO4 
SAE2 (UBA2, UBLE1B) E1 ligase for SUMO1, SUMO2, SUMO3, and 
probably SUMO4 
UBA5 Activates SUMO2 
E3 ligase Examples of proteins modified by the enzyme 
CBX4 HNRNPK, ZNF131 
EGR2 (KROX20) NAB1, NAB2 
MUL1 DNM1L 
NSE2 (NSMCE2) SMC6L1, TRAX, TERF1, TERF2, TINF2, TERF2IP 
PIAS1 PML, CEBPB 
PIAS2 PML, PARK7 (isoform PIAS2-alpha),  
NCOA2, MDM2 (isoform PIAS2-beta) 
PIAS3 CCAR2, MTA1 
PIAS4 CEBPA, PARK7, HERC2, MYB, TCF4, RNF168 
RANBP2 PML, facilitates SUMO1 and SUMO2 conjugation 
RNF212 MSH4, MSH5 
TRIM28 IRF7, TRIM28 
Source: UniProt database (www.uniprot.org) 
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2. Materials and methods 
2.1. Materials 
2.1.1. Chemical reagents used for the cell treatment 
Name      Producer, catalogue number 
Ammonium chloride (NH4Cl)   Sigma-Aldrich, #254134 
Chloroquine     InvivoGen, #tlrl-chq 
Cycloheximide (CHX)    Sigma-Aldrich, #C4859 
DAPI (4’6-diamidino-2-phenylindole) Invitrogen, #D1306 
Etoposide     Sigma-Aldrich, #E1383 
FuGENE® HD Transfection reagent  Promega, #E2311 
Leupeptin     GERBU Biotechnik GmbH, #1335 
MG132     Calbiochem, #474790 
N-ethylmaleimide (NEM)   Sigma-Aldrich, #E3876-5G 
Polyethylenimine (PEI)   Sigma-Aldrich, #408727 
Propidium iodide (PI)    Sigma-Aldrich, #P4170 
Rapamycin     Sigma-Aldrich, #R8781 
 
2.1.2. Buffers and solutions 
Buffer Reagents Concentration 
Protein lysis buffer Tris-HCl (pH=7.4) 
MgCl2 
NaCl 
Glycerol 
NP40 
EDTA 
EGTA 
DTT 
PMSF 
NaF 
Na3VO4 
ß-glycerolphosphate 
Protease inhibitor cocktail 
20 mM 
1 mM 
0.5 M 
20% (v/v) 
0.5% (v/v) 
1 mM 
1 mM 
1 mM 
1 mM 
2.5 mM 
200 mM 
1 mM 
1 tablet / 50 ml 
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Protein lysis buffer for IP Tris-HCl (pH=7.4) 
NaCl 
EDTA 
Triton X-100 
50 mM 
150 mM 
1 mM 
1% (v/v) 
PBS (10x) NaCl 
KCl 
Na2HPO4 ∙ 2H2O 
KH2PO4 
137 mM 
27 mM 
10 mM 
2 mM 
TBS (10x) Tris-HCl (pH=7.4) 
NaCl 
500 mM 
1500 mM 
Reducing sample buffer (5x) Tris-HCl (pH=6.8) 
Glycerol 
SDS 
Bromophenolblue sodium salt 
DTT 
0.27 M 
50% (v/v) 
8.3% (w/v) 
0.12% (w/v) 
0.5 M 
Running buffer (SDS-PAGE) Tris base 
Glycine 
SDS 
25 mM 
192 mM 
0.1% (w/v) 
Transfer buffer (Western blot) Tris base 
Glycine 
Methanol 
25 mM 
192 mM 
20% (v/v) 
Blocking buffer non-fat dry milk in TBST  4% (w/v) 
TE10/1 Tris-HCl (pH=8.0) 
EDTA (pH=8.0) 
10 mM 
1 mM 
PCR buffer (10x) KCl 
Tris-HCl (pH=8.3) 
MgCl2 
0.5 M 
0.1 M 
15 mM 
TAE (50x) Tris acetate 
EDTA (pH=8.2) 
2 M 
0.05 M 
Nicoletti lysis buffer Sodium citrate (pH=7.4) 
Triton X-100 
Propidium iodide 
0.1% (w/v) 
0.1% (w/v) 
50 µg/ml 
S1 Resuspension buffer 
 
Tris-HCl (pH=8.0) 
EDTA 
RNase A 
50 mM 
10 mM 
50 µg/ml 
S2 Lysis buffer NaOH 
SDS 
200 mM 
1% (v/v) 
S3 Neutralization buffer KAc (pH=5.1) 3 M 
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2.1.3. Eukaryotic cell lines and bacterial strains 
Cell line Characteristics 
COS-7 African green monkey (Cercopithecus aethiops, Chlorocebus 
aethiops) kidney fibroblast-like cell line, derived from the CV-1 cell 
line, transformed with an origin defective mutant of SV40, which 
encodes for wild type T antigen. 
HEK293T Human (Homo sapiens) embryonic kidney 293 cells constitutively 
expressing the simian virus 40 (SV40) large T antigen; derivative of 
the 293 cell line. 
POF35-5 CER Mice embryonic fibroblast (MEF) cell line, generated by Dr. Pierre-
Olivier Frappart, carrying CreER(T2) construct, tamoxifen-inducible 
Rint1 conditional knock-out 
POF35-5 EV MEF cell line, generated by Dr. Pierre-Olivier Frappart, carrying Cre 
recombinase construct, EV control cell line 
POF39-4 CER MEF cell line, generated by Dr. Pierre-Olivier Frappart, carrying 
CreER(T2) construct, tamoxifen-inducible Rint1 conditional knock-
out 
POF39-4 EV MEF cell line, generated by Dr. Pierre-Olivier Frappart, carrying Cre 
recombinase construct, EV control cell line 
 
 
Bacterial strain Resistance Experimental purpose 
E. coli DH5α Nalidixic acid Propagating DNA/shRNA plasmids 
E. coli TOP10 Streptomycin Propagating DNA/shRNA plasmids 
E. coli DB3.1 Streptomycin Propagating DNA plasmids containing the ccdB 
operon 
 
 
2.1.4. Culture media 
2.1.4.1. Bacterial culture media 
Medium type Content Manufacturer 
LB-Broth 10 g/l tryptone 
5 g/l yeast extract 
5 g/l NaCl 
pH=7.0 
Carl Roth GmbH, #X968.2 
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LB-Broth agar plates LB-Broth 
2% Agar-agar 
Carl Roth GmbH, #X968.2 
GERBU Biotechnik GmbH, #1340 
 
For the preparation of LB-medium agar plates, 6 g of agar was added to 300 ml of LB-
Broth medium, autoclaved and cooled down to 55°C. At this temperature, antibiotic was 
added: 50 µg/ml of ampicillin or 100 µg/ml kanamycin. Petri dishes were filled with the 
solution. Plates were stored at 4°C. 
 
2.1.4.2. Eukaryotic cell lines culture medium 
Medium Cell type Composition 
D-MEM 
(Dulbecco’s Modified 
Eagle Medium) 
COS-7, HEK293T, MEF 
 
Liquid with L-glutamine, 4500 mg/l 
D-glucose, 25 mM HEPES 
This medium was supplemented with: FCS 
sodium pyruvate 
penicillin/streptomycin 
ß-mercaptoethanol 
L-glutamine 
10% (v/v) 
1 mM 
100U/100µg 
0.1 mM 
2 mM 
Freezing medium COS-7, HEK293T, MEF D-MEM 
FCS 
DMSO 
80% (v/v) 
10% (v/v) 
10% (v/v) 
 
D-MEM and all the reagents were purchased from Gibco, Karlsruhe, with an exception of 
FCS, purchased from Perbio Sciences. 
 
2.1.5. Antibodies 
2.1.5.1. Primary antibodies 
Name (clone) Antigen Isotype Producer,  
catalogue number 
anti-FLAG® (M2)  FLAG Tag mouse monoclonal IgG1 Sigma-Aldrich, #F3165 
anti-FLAG® (M2)  
Affinity Gel 
FLAG Tag mouse monoclonal IgG1 Sigma-Aldrich, #A2220 
anti-GFP (B-2) GFP Tag mouse monoclonal IgG2A Santa Cruz 
Biotechnology,  
sc-9996 
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anti-HA (3F10) HA Tag rat monoclonal IgG1 Roche,  
#11867423001 
anti-HA Affinity Matrix 
(3F10) 
HA Tag rat monoclonal IgG1 Roche,  
#11815016001 
Calreticulin Calreticulin rabbit polyclonal IgG Affinity Bioreagents, 
#PA3-900 
Caspase-3/CPP32 
(Clone 46) 
Caspase-3 mouse monoclonal IgG1 BD Biosciences, 
#611048 
GADD 153 
(F-168) 
GADD 153 
(CHOP10) 
rabbit polyclonal IgG Santa Cruz 
Biotechnology,  
sc-575 
GFP-Trap®_A GFP  ChromoTek,  
#gta-20 
Lasu1/Ureb1 HUWE1 
(LASU1, 
UREB1) 
rabbit polyclonal IgG Bethyl Laboratories, 
#A300-486A 
PARP 
(C2-10) 
PARP1 mouse monoclonal IgG1 Trevigen,  
#4338-MC-50 
RINT1  RINT1 rabbit polyclonal IgG Proteintech Europe, 
#14567-1-AP 
RNF20  
(D6E10) 
RNF20 rabbit monoclonal IgG Cell Signaling,  
#11974 
RNF40  
(KA7-27) 
RNF40 mouse monoclonal IgG1 Sigma-Aldrich,  
#R9029-25UL 
SUMO1 SUMO1 mouse monoclonal IgG generous gift from Dr. 
F. Melchior 
SUMO2 SUMO2 mouse monoclonal IgG generous gift from Dr. 
F. Melchior 
Ubiquitin  
(P4D1) 
Ubiquitin mouse monoclonal IgG1 Santa Cruz 
Biotechnology,  
sc-8017 
 
2.1.5.2. Secondary antibodies 
Name (catalogue number) Antigen Producer,  
catalogue number 
Secondary HRP-conjugated goat polyclonal IgG 
anti-mouse IgG 
Dianova,  
#115-035-003 
Secondary HRP-conjugated goat polyclonal IgG 
anti-rabbit IgG 
Dako, 
#00033131 
Secondary HRP-conjugated goat polyclonal IgG 
anti-rat IgG 
Santa Cruz 
Biotechnology,  
sc-2065 
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2.1.6. Plasmids 
Name, Producer Producer 
MISSION® shRNA HUWE1, pLKO.1  Sigma-Aldrich, #SHCLNG NM_031407 
MISSION® shRNA RNF20, pLKO.1  Sigma-Aldrich, #SHCLNG NM_019592 
MISSION® shRNA RNF40, pLKO.1  Sigma-Aldrich, #SHCLNG NM_014771 
pcDNA3.1-HA  Invitrogen 
pcDNA3.1-HA-Ubiquitin  generous gift from Dr. T. Hofmann 
pFLAG-CMV2  Sigma-Aldrich 
pEGFP-C1  Clontech 
pFLAG-CMV2-RINT1  generous gift from Dr. M. Tagaya 
pFLAG-CMV2-RINT1-N  generous gift from Dr. M. Tagaya 
pFLAG-CMV2-RINT1-M  generous gift from Dr. M. Tagaya 
pFLAG-CMV2-RINT-C  generous gift from Dr. M. Tagaya 
pRK5-HA-Ubiquitin-K29  Addgene #22903 
pRK5-HA-Ubiquitin-K48  Addgene #17605 
pRK5-HA-Ubiquitin-K63  Addgene #17606 
pRK5-HA-Ubiquitin-KO  Addgene #17603 
 
2.1.7. Primers 
Name Primer sequence 
Quantitative PCR 
Oligo-dT (dT)15 
human Huwe1 
 
sense 5’-TGTAATGATGAGCAACTCCTCTT-3‘ 
anti-sense 5’-GGTCCAACAGATCCACCCA3-‘ 
human ß-actin sense 5’-ACCCACACTGTGCCCATCTACGA-3′ 
anti-sense 5’-CAGCGGAACCGCTCATTGCCAATGG-3′ 
Quantitative PCR primers were designated using “Roche Universal ProbeLibrary for Human” 
(www.lifescience.roche.com) 
Generation of truncated human RINT1 mutants 
Rint1-Δ1 
 
sense: 5'-AAGCGGCCGCAGAAGTTGGAAATGACCTTAAATC-3' 
anti-sense: 5'-AAGGATCCTTATTTTCCAGTATTAGGCCAATTTG-3' 
Rint1-Δ2 
 
sense: 5'-AAGCGGCCGCACAATTTCTTAATCAGTTTCTGGAGC-3' 
anti-sense 5'-AGGATCCTTATTTTCCAGTATTAGGCCAATTTGTCC-3' 
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Rint1-Δ3 sense: 5'-AAGCGGCCGCATACTCTCTTCCTGCCTCCCC-3' 
anti-sense: 5'-AAGGATCCTTATTTTCCAGTATTAGGCCAATTTGTCC-3' 
Site directed mutagenesis – Rint1 putative ubiquitination site 
Rint1-A71G sense: 5'-GTGACGAAAGGAGGAACCTCGAGGAG-3' 
anti-sense: 5'-CTCCTCGAGGTTCCTCCTTTCGTCAC-3' 
  
2.1.8. shRNA 
Name shRNA sequence 
shRNA HUWE1 CGGGCTCCCACTATAACCTCACTTCTCGAGAAGTGAGGTTATAGTGGGA
GCTTTTTG 
shRNA RNF20 CCGGCGGAGGAACTAGACATTAGAACTCGAGTTCTAATGTCTAGTTCCT
CCGTTTTTG 
shRNA RNF40 CCGGGCAGAAGTTTGAGATGCTGAACTCGAGTTCAGCATCTCAAACTTC
TGCTTTTT 
 
2.1.9. Commercial kits and materials 
Commercial kit/material    Manufacturer, catalogue number 
ApopTag Plus® Fluorescein In Situ    Chemicon International, #S7111 
Apoptosis Detection Kit 
Gateway® BP Clonase® II Enzyme Mix  Life Technologies, #11789-020 
Gateway® LR Clonase® II Enzyme Mix  Life Technologies, #11791-020 
GeneAmp RNA PCR     Applied Biosystems, #4312765 
KOD Hot Start DNA Polymerase   Novagene, #71086-3 
LigaFast™ Rapid DNA Ligation System  Promega, #M8221 
Power SYBR Green PCR Master Mix   Applied Biosystems, #4368708 
ProLong® Gold Antifade Mountant   ThermoFisher Scientific, #P36930 
QIAGEN Plasmid Plus Maxi Kit   Qiagen, #12965 
QIAquick Gel Extraction Kit    Qiagen, #28706 
QIAquick PCR purification Kit    Qiagen, #28106 
Reverse Transcriptase    Applied Biosystems, #4311235 
RNeasy Mini Kit     Qiagen, #74106 
Western Lightning® Plus-ECL    PerkinElmer, USA, #NEL103001EA 
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2.1.10. Instruments 
Instrument       Manufacturer 
Agarose gel electrophoresis chamber   Bio-Rad 
Bacterial culture incubator/shaker    Eppendorf 
Basic pH Meter PB-11     Sartorius 
Blotting system, Mini Trans-Blot® Cell   Bio-Rad 
Centrifuges: 
 5415R       Eppendorf 
 5418       Eppendorf 
 5804R       Eppendorf 
Chemiluminescence visualization system   Bio-Rad 
CO2-cell culture incubator     Sanyo 
DNA Engine Thermal Cycler PTC-200   Bio-Rad 
Electrophoresis power supply, PowerPac Basic  Bio-Rad 
Electroporation system, Gene Pulser Xcell™  Bio-Rad 
Gel documentation system: 
 UV Transilluminator, UST-20M-8K   Biostep 
 Digital camera, EOS 500D    Canon 
 EF 28mm f/1.8 USM     Canon 
Heat block       Eppendorf 
Light microscope      Leica Microsystems 
MicroPulser electroporation cuvettes   Bio-Rad 
Magnetic stirrer, MR Hei-Standard    Heidolph Instruments 
Microwave oven      Samsung 
Platform shaker, Unimax 1010 orbital   Heidolph Instruments 
Quartz cuvettes      Sigma-Aldrich 
Rotary shaker       Stuart 
Sonicator       Qsonica 
Spectrophotometer      Bio-Rad   
Spectrophotometer NanoDrop 1000    PEQLAB 
Thermomixer compact     Eppendorf 
Vortex Genie 2      Scientific Industries 
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2.1.11. Software 
Software      Company/Link 
BDM-PUB      www.bdmpub.biocuckoo.org 
GENtle, version 1.9.4     Magnus Manske, University of Cologne 
GPS-SUMO      sumosp.biocuckoo.org/online.php 
ImageJ, version 1.46r     Public domain, Wayne Rasband, NIH 
Multi-Omics Profiling Expression Database  www.proteinspire.org 
PHOSIDA      www.phosida.com 
PhosphoSitePlus     www.phosphosite.org 
Phylogeny.fr      http://phylogeny.lirmm.fr 
PRALINE      www.ibi.vu.nl/programs/pralinewww 
Roche Universal ProbeLibrary for Human  www.lifescience.roche.com 
Scaffold, version 4.0.7.    Proteome Software 
Sequence Detection Software   Applied Biosystems 
UbPred      www.ubpred.org 
 
 
 
2.2. Methods 
2.2.1. Molecular biological methods 
2.2.1.1. Transformation of plasmid DNA in competent bacteria 
Competent E. coli bacteria (50 µl) were thawed on ice and a plasmid (25 ng) was 
transferred to the bacterial solution. Bacterial solution was subsequently gently mixed 
and incubated on ice for 30 min After this time, a heat shock at 42°C for 50 sec in water 
bath was performed. Then, the reaction mix was incubated on ice for 3-4 min, and 250 µl 
of LB-medium was added. Eppendorf tube containing the solution was transferred to a 
shaker and incubated for 1h at 37°C, 300 rpm. Afterwards, 100 µl of the mixture was 
transferred to LB-agar selective plate containing the appropriate antibiotic (ampicillin or 
kanamycin). The plate was incubated o/n at 37°C. 
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2.2.1.2. Preparation of plasmid DNA 
2.2.1.2.1. Large-scale purification of plasmid DNA 
Large-scale plasmid purification was performed using commercially available QIAGEN 
Plasmid Plus Maxi Kit, according to the manufacturer’s protocol. Bacteria containing the 
transformed plasmid were cultured o/n in 300 ml of LB-medium, containing appropriate 
antibiotic for selection pressure in an incubator at 37°C, 300 rpm. The next day, bacteria 
was harvested by centrifugation at 6000 x g, for 15 min at 4°C. The supernatant was 
carefully discarded and the bacterial pellet was resuspended in 10 ml of the supplied 
buffer P1. In order to lyse the cells, 10 ml of buffer P2 was added, the content of the tube 
was mixed thoroughly by inverting it 4-6 times, and the mixture was incubated at RT for 5 
min To stop the lysis, 10 ml of chilled buffer P3 was added. Solution was mixed, incubated 
on ice for 20 min and subsequently centrifuged at 20000 x g for 30 min at 4°C. The 
supernatant containing plasmid DNA was applied to equilibrated with 10 ml of QBT buffer 
QIAGEN-tip 500 column. The column was washed two times with 30 ml of buffer QC. In 
order to elute the plasmid DNA, 15 ml of buffer QF was applied to the column and the 
eluate was collected into fresh tube by free-flow. Precipitation of the DNA was performed 
by adding 10.5 ml (0.7x volume) of RT isopropanol to the eluate and by immediate 
centrifugation of mixed solution at 15000 x g for 30 min at 4°C. The DNA pellet was 
washed with 5 ml of RT 70% ethanol and centrifuged again at 15000 x g for 10 min at 4°C. 
The ethanol was discarded, the DNA pellet was air-dried for 10-15 min and resuspended 
in 100 µl of TE buffer. The quantity and the quality of purified plasmid DNA were verified 
by agarose gel electrophoresis and using NanoDrop 1000 spectrophotometer. 
 
2.2.1.2.2. Preparation of plasmid DNA using home-made buffers 
Purification of DNA plasmids up to 25 µg was performed using home-made S1, S2 and S3 
buffers. 1.5 ml of o/n bacterial culture containing the plasmid was centrifuged at 14000 x 
g for 1 min. and the supernatant was carefully removed. Bacterial pellet was resuspended 
in 250 µl of buffer S1 and 250 µl of S2 lysis buffer was added. The tube was inverted 5-6 
times and incubated on ice for 5 min Next, 350 µl of S3 neutralization buffer was added, 
the tube was again inverted 5-6 times and incubated on ice for additional 5 min 
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Subsequently, the tube was centrifuged for 10 min at 14000 x g and the supernatant (750 
µl) was transferred to a fresh 1.5 ml tube. Single volume (750 µl) of ice-cold 100% ethanol 
was added, the tube was vortexed and centrifuged again for 10 min at 14000 x g. The 
pellet of plasmid DNA was washed with 1 ml of ice cold 70% ethanol and the tube was 
centrifuged as before. The supernatant was carefully discarded, the pellet was air-dried 
for 10-15 min at RT and resuspended in 30-50 µl of TE10/1 buffer. The quantity and the 
quality of purified plasmid DNA was verified by agarose gel electrophoresis and using 
NanoDrop 1000 spectrophotometer. Briefly, the spectrophotometer was equilibrated 
with 1 µl of H2O pipetted onto the lower measurement pedestal. Then, 1 µl of DNA 
sample was placed onto measurement pedestal and the reading was initiated using the 
operating software on the PC. The absorbance was recorded at 260 nm and 280 nm. 
 
2.2.1.3. Restriction enzyme digestion and ligation of DNA fragments 
Restriction enzyme-mediated digestion of DNA was performed as one of the steps for 
cloning of the DNA fragments into another plasmid, or in order to verify the sequence of 
cloned construct according to a restriction map. Plasmid DNA and DNA fragments were 
digested with appropriate restriction enzymes (and their concentrations), typically for 4 h 
at 37°C. Following reaction mixture were prepared (volumes are given for one reaction 
vial):  
Restriction digest of DNA fragments obtained by PCR-mediated synthesis: 
Reagent:    Volume: 
DNA fragment    5 µl (final concentration: 1 µg)  
restriction enzyme   1 µl (10 U) 
respective restriction buffer 10x 3 µl 
H2O      to a final volume of 30 µl 
Restriction digest of plasmid DNA: 
Reagent:    Volume: 
plasmid    1 µg  
restriction enzyme   1 µl (10 U) 
respective restriction buffer 10x 3 µl 
H2O      to a final volume of 30 µl 
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DNA fragments were subsequently separated on an agarose gel, and purified using 
QIAquick Gel Extraction Kit (Qiagen), according to the manufacturer’s protocol. For the 
ligation, following reaction was performed: 
Reagent:   Volume: 
vector DNA   100 ng 
insert DNA   33 ng 
2X Rapid Ligation Buffer 5 µl 
T4 DNA Ligase (Weiss units) 3 U 
Reaction mix was incubated o/n at 4°C. 
 
2.2.1.4. Gateway® Recombination Cloning Technology 
Gateway® Recombination Cloning Technology was used to quickly and efficiently clone 
genes into multiple destination vectors, without a need to use restriction enzymes, ligase 
and subcloning steps. Gateway cloning was performed in two steps and following 
manufacturer’s protocol. First, a BP recombination reaction between an attB-flanked DNA 
fragment and an attP-containing donor vector was performed, to create an entry clone. 
During a second step a LR recombination reaction between an attL-containing entry clone 
and an attR-containing destination vector was performed to generate an expression 
clone. Reactions were prepared as follows: 
 
BP recombination reaction: 
Reagent:    Volume: 
attB-PCR product   1-7 µl (10 ng/µl, final amount ~15-150 ng)  
pDONR™ vector   1 µl (150 ng/µl) 
5X BP Clonase™ reaction buffer 2 µl 
TE10/1      to final volume of 8 µl 
 
Reaction was incubated at RT for 1 h. Then, 2 µl of 2 µg/µl proteinase K solution was 
added and the mix was incubated at 37°C for 10 min Competent E. coli were transformed 
with the reaction mix and selected for appropriate antibiotic-resistant entry clones. 
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LR recombination reaction: 
Reagent:    Volume: 
entry clone    1-7 µl (50-150 ng)  
destination vector   1 µl (150 ng/µl) 
5X LR Clonase™ reaction buffer 2 µl 
TE10/1      to final volume of 8 µl 
 
Reaction was incubated at RT for 1 h. Then, 2 µl of 2 µg/µl proteinase K solution was 
added and the mix was incubated at 37°C for 10 min. Competent E. coli were transformed 
with the reaction mix and selected for the appropriate antibiotic-resistant expression 
clones. 
 
2.2.1.5. Total cellular RNA extraction 
Total RNA was extracted using RNeasy Mini Kit (Qiagen). Briefly, cells were first lysed and 
homogenized by adding 600 µl of buffer RLT. Single volume of ethanol 70% (in RNase-free 
water) was added to the lysate to provide ideal binding conditions, and mixed by 
pipetting. 700 µl of the sample was loaded onto the RNeasy mini spin column placed in a 
2 ml collection tube. Tube was centrifuged for 15 s at 8000 x g. Contaminants were 
washed away with sequential washing with buffer RW1 (700 µl) and RPE (500 µl, twice), 
and spinning for 15 s at 8000 x g. RNA was eluted in 30 µl H2O by centrifugation for 1 min 
at 8000 x g. RNA concentration was measured as described for DNA (section 2.2.1.2.2.). 
The RNA samples were stored at -80°C. 
 
2.2.1.6. Reverse-transcription reaction for cDNA generation (RT) 
Total RNA extracted using RNeasy Mini Kit was subjected to mRNA-specific RT-PCR 
reaction to synthesize cDNA. Buffers and reagents were from the RNA PCR Core Kit 
(Applied Biosystems). The reaction mixture was prepared as follows (volumes are given 
for one reaction vial): 
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Reagent:     Volume: 
10x PCR buffer (without MgCl2)   5 µl (final concentration: 1x) 
25 mM MgCl2      10 µl (final concentration: 5 mM) 
10 mM dNTPs mix    5 µl (final concentration: 1 mM) 
20 U/µl MuLV Reverse Transcriptase  2.5 µl (final concentration: 2.5 U/µl) 
Oligo dT primer (50 µM in 10 mM Tris)  2.5 µl (final concentration: 2.5 µM) 
RNA      2.5 µg 
RNase-free H2O     to final volume of 50 µl 
 
The mixture was incubated in a thermocycler using following conditions: 
 
Step:      Time and temperature: 
annealing     15 min at 25°C 
elongation     1h at 42°C 
inactivation of reverse transcriptase  5 min at 95°C 
 
Synthesized cDNA was stored at -20°C. 
 
2.2.1.7. Polymerase chain reaction (PCR) 
Classical polymerase chain reaction (PCR) mix was prepared as following (volumes are 
given for one reaction vial): 
Reagent:    Volume: 
10x PCR buffer     2.5 µl 
25 mM MgCl2    2.5 µl 
5 U/µl Taq DNA Polymerase  0.4 µl 
10 mM dNTPs mix   0.5 µl 
100 pmol primer forward  0.75 µl 
100 pmol primer reverse  0.75 µl 
DNA template    1 µl 
H2O     to volume of 25 µl 
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Steps of the PCR reaction used for gene cloning were as following: 
 
Step:      Time and temperature: 
initialization     5 min at 95°C 
denaturation     1 min at 95°C 
annealing     1 min at 58°C  30-35 cycles 
elongation     2 min at 72°C 
termination     10 min at 72°C 
final hold     4°C 
 
The PCR conditions (annealing temperature, elongation time) were optimized for specific 
genes and primers. The PCR products were electrophoretically separated on an agarose 
gel containing ethidium bromide. 
 
2.2.1.8. Site directed mutagenesis (SDM) 
In order to introduce point mutation to the DNA sequence, site directed mutagenesis 
(SDM) using linear amplification PCR technique was performed. As a first step, primers 
introducing the desired mutation into the amplified sequence were designed. The criteria 
for primer design were as follows: melting temperature (Tm) of the primers was higher 
than 65°C, and the mutation site was located in the middle of the primer sequence. Total 
volume of PCR reaction mix was of 50 µl. In order to minimalize the chances of 
introducing unwanted mutations, high fidelity KOD Hot Start DNA Polymerase (Novagene) 
was used. Maximum 20 cycles were executed. Following PCR, in order to digest 
methylated template plasmid, reaction mix was subjected to the restriction reaction with 
DpnI enzyme, for 1h. Finally, PCR mutated product was transformed into competent E. 
coli bacteria. Clones were analyzed using restriction digest mapping and subsequently 
sequenced, to confirm the occurrence of a desired mutation. 
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2.2.1.9. Purification of PCR products and other DNA fragments 
Purification of PCR products/DNA fragments was performed prior to restriction enzyme 
digestion and/or sequencing using QIAquick PCR purification kit (Qiagen) and according to 
the manufacturer’s protocol. Briefly, 5 volumes of buffer PB were added to 1 volume of 
the PCR product and mixed (until a color of the mixture turned yellow, indicating pH value 
equal or lower than 7.5, suitable for DNA/column binding). Sample was applied on the 
column and centrifuged for 1 min at 17 000 x g. All the following centrifugation steps 
were carried out under the same conditions. Next, the column was washed with 0.75 ml 
of buffer PE and centrifuged. Additional spinning was performed, to remove residual 
wash buffer from the column.  QIAquick column was then placed in a fresh collecting tube 
and the purified DNA was eluted with 30-50 µl of buffer EB. 
 
2.2.1.10. Quantitative real-time PCR (qRT-PCR) 
The cDNA was pipetted into a 96-well plate. Each reaction was performed as triplicate of 
total volume of 25 µl. qPCR was performed using Power SYBR Green PCR Master Mix 
(Applied Biosystems). Quantitative RT-PCR reaction mixture consisted of: 
- 1 µl of reverse-transcribed cDNA (product of a reaction described at p. 2.2.1.6) 
- 1 µl forward/reverse primer respectively;  
primer stock solutions were:  for HUWE1 – 10 µM (400 pM end concentration) 
    for ß-actin – 5 µM (200 pM end concentration) 
- 9.5 µl of H2O 
- 12.5 µl of the Power SYBR Green PCR Master Mix 
Gene expression was analyzed using the 7500 Real-Time PCR Systems and Sequence 
Detection Software v.2.0.2. (Applied Biosystems). Huwe1 gene expression level was 
calculated relatively to ß-actin mRNA as an endogenous reference using the following 
formula: X = 2-ΔCt, where Ct stands for cycle threshold and ΔCt = Ctgene of interest – Ctreference 
gene, i.e. 2
-(ΔCt of Huwe1 – ΔCt of ß-actin). The resulting relative increase in reporter fluorescent dye 
emission was monitored for 42 cycles. The mean expression values +/- SD were calculated 
from triplicated samples. 
 
Materials and methods 
 
56 
 
2.2.1.11. Agarose gel electrophoresis 
Agarose gel electrophoresis was applied to separate DNA fragments according to their 
size. The percentage of the gel was dependent on the predicted size of DNA fragments to 
be detected and separated. The agarose suspension in TAE buffer, usually between 0.7% 
(w/v) and 2% (w/v), was boiled in a microwave oven until completely dissolved, and 
cooled down to the temperature ~50°C. Next, ethidium bromide was added to the final 
concentration of 0.003% and the agarose gel was poured to the cast and cooled down until 
set. The DNA samples, mixed with 1/5 volume of 5x loading buffer, were loaded on the gel. 
The gel was run for 30 min to 1 h, at 100 V. DNA fragments were visualized with the UV 
transilluminator. 
 
2.2.1.12. Purification of PCR products and DNA fragments from 
agarose gel 
PCR products and DNA fragments subjected to cloning, were purified from agarose gel 
using QIAquick Gel Extraction kit according to manufacturer’s protocol. First, slice of the 
agarose gel containing desired DNA fragment was excised with a scalpel, transferred to an 
Eppendorf tube and weighed. Next, to 1 volume of the gel, 3 volumes of QG buffer were 
added. Tube was incubated at 50°C for 10 min or until the gel slice completely dissolved. 
To increase the yield of DNA fragments, 1 gel volume of isopropanol was added to the 
sample, and mixed. Afterwards, sample was applied to the QIAquick column and 
centrifuged for 1 min at 10000 x g. The DNA was washed with 0.75 ml of PE buffer, and 
centrifuged using the same conditions. To remove any residues of PE buffer, 
centrifugation step was repeated after discarding the flow-through. The DNA was eluted 
into the fresh tube using 30 µl of EB buffer. The concentration and the quality of the DNA 
was measured by NanoDrop 1000 and agarose gel electrophoresis. Samples were stored 
at -20°C for further use. 
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2.2.1.13. Transient transfection and shRNA-mediated knock-down 
2.2.1.13.1. Electroporation of mammalian cells 
COS7 cells were transiently transfected with different expression plasmids using 
electroporation system – Gene Pulser Xcell™ (Bio-Rad). For one electroporation, two T175 
flasks of COS7 cells growing in confluence were used. Briefly, cells were washed with 20 
ml of PBS and trypsinized with 5 ml of trypsin-EDTA (0.25%) solution for 5 min at 37°C. In 
order to stop the trypsinization process, 10 ml of MEF medium was added and the cells 
were collected to 50 ml Falcon tubes. Next, cells were centrifuged for 5 min at 1000 rpm 
and, after discarding the medium, washed with 10 ml of PBS. Centrifugation step was 
repeated. 40 µg of plasmid DNA intended for electroporation was placed in 0.4 cm gap 
electroporation cuvette. COS7 cells were resuspended in 0.8 ml of ice-cold PBS and 
transferred to the cuvette containing plasmid. Cells were electroporated with 400 V, 960 
µF capacitance and the resistance +∞. Electroporated cells were immediately transferred 
to 20 ml of MEF medium and centrifuged for 5 min at 1000 rpm. The cell pellet was 
resuspended in 50 ml of fresh MEF medium and the cells were plated in 5 x T75 flasks. 
 
2.2.1.13.2. Polyethylenimine (PEI)-mediated transient transfection 
HEK293T cells were transiently transfected with mammalian expression plasmids using 
branched polyethylenimine (PEI) transfection reagent. PEI solution used for transfection 
was prepared as follows: 100 µl of PEI stock solution (10 mg/ml PEI in H2O, density=1.030 
g/ml) was diluted in 10 ml of ddH2O or 1x PBS. Solution was kept at 4°C. One day before 
the procedure, cells were seeded the way they reach 70% confluency on the day of 
transfection. For 150 mm dish, 6.5 x 103 of HEK293T cells was seeded and incubated 
overnight at 37°C. Shortly before the transfection, DNA plasmid and PEI stock solution 
were diluted in DMEM as follows: 13 µg of plasmid in 3.125 ml of DMEM and 2.5 µg of PEI 
per 1 µg of plasmid DNA in 3.125 of DMEM. Diluted PEI solution was combined with the 
DNA solution, immediately vortexed and incubated at RT for 10 min. MEF medium was 
aspirated from 150 mm dish and replaced with 30 ml of DMEM. DNA-PEI mix was added 
drop-wise to the cells evenly over the entire surface of the dish. After 6 h of incubation at 
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37°C, PEI-containing DMEM was replaced by MEF medium. Next, cells were incubated for 
24-48 h at 37°C in CO2 atmosphere, and harvested for the experiment. 
 
2.2.1.13.3. shRNA-mediated gene knock-down 
The expression of target genes (Huwe1, Rnf20, Rnf40) was knocked-down by selective 
inactivation of corresponding mRNA induced by the short hairpin RNA (shRNA). The 
experiments were performed simultaneously with transient transfection of RINT1 
expression construct in order to analyze the effect of knock-down on RINT1 protein 
stability. Briefly, plasmid encoding shRNA and plasmid encoding RINT1, were transiently 
introduced to the cells using FuGENE® HD transfection reagent, according to 
manufacturer’s instructions. The ratio of FuGENE® HD : DNA used was 2:1, and the ratio 
of shRNA plasmid to DNA plasmid was 5:1. Cells were harvested 48h post-transfection, 
lysed and analyzed by Western blot. 
 
2.2.2. Cellular biological methods 
2.2.2.1. Cell culture  
All the cell lines were propagated at 37° in an incubator with a humidified 5% CO2 
atmosphere. Cells were grown as adherent culture, maintained by replacement of fresh 
MEF medium every 2-3 days and passaged when reached the confluency of 80%. All cell 
culture work was performed under sterile conditions. 
 
2.2.2.2. Maintenance of eukaryotic cell lines 
For a long-term use, cell lines were stored in liquid nitrogen, and for a short-term use, at  
-80°C. 
Freezing of the cells 
Adherent cells from one confluent T175 culture flask were harvested by washing them 
with 15 ml of PBS 1x, trypsinizing with 5 ml of trypsine-EDTA (0.25%) for 5 min at 37°C, 
and centrifuging in 15 ml of MEF medium for 5 min at 1000 rpm. Next, the cell pellet was 
resuspended in 10 ml of freezing medium (see Materials section) and evenly distributed 
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in 10 x 1ml Nunc™ cryogenic tubes (Thermo Scientific). Tubes with cells were kept on ice 
for 2 min and placed at -80°C or in the liquid nitrogen, according to the purpose of their 
use.  
 
Thawing of the cells 
Thawing procedure is characterized by a rapid increase in temperature and fast exchange 
of culture medium in order to avoid toxic effects of the high content of DMSO in the 
freezing medium. To thaw the cell line, cryo tubes with frozen cells were placed directly in 
the water bath at 37°C. As soon as frozen medium started to thaw, cells were 
immediately transferred into Falcon tube with 10 ml of pre-warmed MEF medium and 
resuspended. Cell suspension was centrifuged for 5 min at 1500 rpm. Cell pellet was 
washed with 10 ml of PBS, centrifuged again for 5 min at 1500 rpm, and resuspended in 5 
ml of MEF medium. Finally, medium with cells was pipetted to the T25 culture flask and 
placed at 37°C in the cell incubator. 
 
2.2.2.3. Flow cytometric analysis of cell death 
2.2.2.3.1. Plasma membrane permeabilization 
Cell death analysis was performed using flow cytometry. Dying cells shrink and become 
more granular resulting in a lower forward scatter index (FSC) and increased side scatter 
index (SCC), respectively. Death-associated loss of membrane impermeability can be 
monitored by using propidium iodide (PI) staining (SCC/strength of PI emission signal). In 
living cells, PI does not penetrate. However, PI stains nuclei of dead cells fluorescent red. 
Briefly, cells were centrifuged for 5 min at 1000 rpm, washed with PBS, suspended in PBS 
and stained by mixing with 1:1 volume of PI solution (5 µg/ml in PBS). Next, cells were 
immediately subjected to FACS analysis (PI excitation wavelength is 535 nm and emission 
wavelength is 617 nm).  
The results are presented as percentage of “specific cell death”, calculated according to 
the following formula (Ehret, Westendorp et al. 1996): 
                                              dead cells [%] – dead cells [%] (untreated control) 
                                                        100 – dead cells [%] (untreated control) 
= 
  “Specific 
cell death” [%] x 100 ( ) 
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2.2.2.3.2. Analysis of apoptotic nuclear fragmentation 
Fragmentation of cell nuclei was analyzed essentially according to the method of Nicoletti 
et al. (Nicoletti, Migliorati et al. 1991). Cell nuclei were isolated by cell lysis and staining 
with PI using following buffer: 0.1 % Na-citrate, 0.1% (v/v) Triton X-100 and 50 g/ml PI. 
Measurement of fluorescence signal enables an assessment of the amount of subG1 
nuclear fraction, which is characteristic for apoptotic nuclear fragmentation. Cells were 
centrifuged at 2000 rpm for 5 min, washed with PBS, and carefully suspended in 100 l of 
Nicoletti lysis buffer. After overnight lysis at 4oC in dark, isolated nuclei were analyzed by 
flow cytometry (PI fluorescence readout). 
 
2.2.2.4. Flow cytometric analysis of cell cycle 
Cells were harvested and suspended in a 1 ml of wash buffer (PBS + 0.1% FBS), then fixed 
by drop-wise addition of 3 ml of absolute ethanol while vortexing. Next, cells were 
incubated o/n at 4oC, washed with PBS and suspended in 1 ml of the PI staining solution 
(3.8 mM Na-citrate, 40 g/ml PI) supplemented with 50 l of RNAase A stock solution (10 
g/ml RNase A, Qiagen). Subsequently, samples were analyzed by FACS. 
 
2.2.2.5. DAPI and TUNEL staining 
In order to investigate morphological changes of nuclei characteristic for apoptotic 
fragmentation, labeling of nuclear DNA in Rint1 inducible knock-out MEF cell lines was 
performed. Cells were stained using 4’6-diamidino-2-phenylindole (DAPI) blue-fluorescent 
dye (Invitrogen, #D1306) according to the manufacturer’s protocol. Briefly, cells growing 
on the microscope slides were fixed and permeabilized (4% paraformaldehyde in PBS and 
0.1% Triton X-100 in PBS, respectively), followed by equilibration with PBS. Diluted DAPI 
stock solution (end concentration 300 nM in PBS) was applied on the cells and incubated 
for 5 min. Samples were rinsed 2-3 times in PBS, drained and mounted with a ProLong 
Gold antifade reagent (ThermoFisher Scientific, #P36930). 
Further verification of putative apoptosis was performed using ApopTag Plus® Fluorescein 
In Situ Apoptosis Detection Kit (Chemicon International, #S7111) following manufacturer’s 
manual. This technique uses principles of the TUNEL (terminal deoxynucleotidyl 
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transferase dUTP nick end labeling) assay and allows for detection of single- and double-
stranded DNA breaks . 
 
2.2.2.6. 4-hydroxytamoxifen (OHT)-induced knock-out 
Mouse embryonic fibroblast (MEF) cell lines were generated by Dr. Pierre-Olivier 
Frappart. Cells were isolated from embryonic day E13.5 Rint1 Flox/Flox embryos and 
immortalized following the “3T3 protocol” (Todaro and Green 1963). After 
immortalization, MEFs were transduced with retroviruses carrying pMSCVpuro construct 
(to generate EV control) or pMSCVpuro-Cre-ER(T2) (construct encoding Cre recombinase 
under control of estrogen receptor-driven promoter); for cell line specification see 
Materials and Methods p. 2.1.3.. To delete Rint1, cells were treated with 1 μM 4-
hydroxytamoxifen (4-OHT) (Sigma-Aldrich, #H7904) for 48 h or 96 h. The knock-out 
efficiency was monitored by genomic DNA PCR, with following primers: for WT allele: 
RINT7512F (5’-TTCCTACTGACTTGCTGTGAT-3’) and RINT8345R (5’-
ACTTCTGGATGACTGAGGAC-3’), for Δ allele: RINT6542F (5’-TAACCCCTGACCCATCTCTC-3’) 
and RINT8345R. 
 
2.2.3. Biochemical methods 
2.2.3.1. Yeast two-hybrid assay 
The yeast two-hybrid assay was performed by Dr. Stefan Push, University of Heidelberg, 
Heidelberg, Germany as previously described (Weiler, Blaes et al. 2014). 
 
2.2.3.2. SDS-PAGE and Western blotting 
Cell pellet was resuspended in ice-cold lysis buffer with protease inhibitor mixture and 
incubated for 30 min at 4°C on a rotary shaker. Next, cell lysates were sonicated for 4-5 
sec, 30% of amplification, and centrifuged at 14000 x g for 15 min at 4°C. The supernatant 
was transferred to a fresh tube and the protein concentration was determined using the 
spectrophotometric analysis. Aliquots of cell lysates (e.g. 40 µg) were separated using 
SDS-facilitated polyacrylamide gel electrophoresis (SDS-PAGE). Separation conditions 
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were: polyacrylamide gels of single percentage (8%, 10% or 12%, depending on the 
protein size), or a gradient gel (4-15%), used in case of HUWE1-specific IP experiments 
(MW 482 kDa) and 100 V with 25 mA. The gel was blotted to nitrocellulose membrane 
(Hybond ECL, GE Healthcare Life Sciences) o/n using wet transfer system (Bio-Rad) at 4°C 
(with ice coat and constant mixing). Transfer conditions were 30 V (const.) and 90 mA. 
After blotting, membranes were blocked by 1 h washing in blocking solution (4% 
powdered milk in TBST 0.05%), washed 10 min with TBST 0.05% and incubated for 1h or 
o/n with primary antibody (suspended in 4% powdered milk, TBST 0.05%), at RT or 4°C, 
respectively. Then, membranes were washed 3 x 10 min with TBST 0.1% solution and 
stained with horseradish peroxidase-conjugated secondary antibody for 1 h at RT. Next, 
membranes were 3 x washed, each washing step of 10 min, with TBST 0.1%, TBST 0.05% 
and TBS, consecutively. The protein-specific signal was detected by enhanced 
chemiluminescence using Western Lightning Chemiluminescence Reagent (PerkinElmer), 
according to the manufacturer’s protocol. Signal intensity was analyzed by densitometry 
using ImageJ software. 
 
2.2.3.3. Protein immunoprecipitation 
Cells were lysed using lysing buffer for immunoprecipitation experiments (see Materials 
section). Immunoprecipitation of tag-fused proteins was performed using anti-FLAG® M2 
Affinity Gel (Sigma-Aldrich), anti-HA Affinity Matrix (Roche) or GFP-Trap®_A (ChromoTek), 
depending on the protein’s tag and according to manufacturer’s protocol. Briefly, cell 
lysates were incubated with specific antibody conjugated with matrix (e.g. agarose 
beads), for 30 min to o/n, at 4°C. Next, matrix was washed 6 x with ice-cold TBS buffer. 
Tag-fused protein was eluted using SDS-PAGE sample buffer and by boiling the samples 
for 5 min at 95°C.  Samples were subjected to Western blot analysis immediately after 
being eluted. 
 
2.2.3.4. Mass-spectrometry analysis 
Mass spectrometry analysis of immunoprecipitated GFP-tagged RINT1 protein and GFP-
tagged empty vector control, was performed by the Genomics and Proteomics Core 
Facility, DKFZ, Heidelberg, Germany, and by the Core Facility for mass spectrometry, 
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ZMBH, Heidelberg, Germany. Analysis of obtained results was performed using Scaffold4 
software. 
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3. Results 
3.1. RINT1 degradation 
3.1.1. RINT1 has a short half-life 
Despite the ubiquitous expression of RINT1 in a large number of mammalian tissues (e.g. 
according to BioGPS database, biogps.org, and others, see Introduction section), 
endogenous RINT1 levels are hardly detectable using commercially available antibodies. 
Although low specificity of the antibodies definitely contributes to this observation, it also 
indicates putative fast turnover and/or low stability of the protein. Indeed, the initial 
study showed that the level of overexpressed RINT1 decreased fast and spontaneously 
during 24-48 h upon the expression (Fig. 18A), suggesting a short half-life of RINT1. 
Consistently with this assumption, an inhibition of protein translation by cycloheximide 
(CHX) in COS-7 cells expressing N-terminally FLAG-tagged RINT1, resulted in almost 
complete depletion of RINT1 levels already within 8 h of the treatment (Fig. 18B). A 
significant decrease of the protein level was observed after 1 h of the CHX administration 
(Fig. 10B). 
A.       B. 
 
 
 
 
 
 
 
 
 
Figure 18. RINT1 is an unstable protein. (A) Overexpressed RINT1 levels in COS-7 cells decrease 
fast and spontaneously during 24 h post-transfection. (B) FLAG-RINT1 levels in COS-7 cells 
significantly decrease upon cycloheximide treatment. 
 
To verify whether the N-terminal position of the FLAG-tag influences fast decay of RINT1 
upon the CHX treatment, an experiment with C-terminally tagged protein version was 
performed. The results were similar to the ones previously described: FLAG-C-RINT1 
levels significantly decreased after 1h of protein biosynthesis inhibitor treatment, and 8 h 
of drug activity was enough to deplete protein from the cells completely (Fig. 19). This 
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experiment showed, that low stability of overexpressed RINT1 is not tag-position-
dependent. 
 
 
 
 
 
 
 
 
 
 
Figure 19. Fast cellular turnover of overexpressed RINT1 is not tag-position-dependent. COS-7 
cells were electroporated with indicated plasmids. At 24 h post-transfection, the cells were 
incubated with 12.5 µg/ml CHX for 0 h, 1 h and 8 h and were collected for WB. ß-tubulin was used 
as a control. 
 
 
In order to quantify RINT1 degradation and to determine the exact half-life of the protein, 
a CHX-chase study was performed. To do this, HEK293T cells were transfected with FLAG-
N-RINT1 or FLAG-C-RINT1 plasmids, and the CHX was added. Cellular levels of FLAG-RINT1 
were detected by Western blot (WB) at indicated time points, and quantified using 
ImageJ software. As expected, RINT1 decay was fast and resulted in total depletion after 6 
h of the CHX treatment (Fig. 20). The half-life of the N-terminally FLAG-tagged protein 
was calculated to be 38.5 min, and 40.46 min for the C-terminally tagged protein version. 
 
 
 
 
 
Cells: COS7 
Construct: N-terminal FLAG-RINT1 
Cells: COS7 
Construct: C-terminal FLAG-RINT1 
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A. 
 
 
 
 
 
 
 
 
 
 
B. 
 
 
 
 
  
 
 
 
 
 
Figure 20. RINT1 has a short half-life. HEK293T cells were transfected with plasmid FLAG-N-RINT1 
(A) or FLAG-C-RINT1 (B). At 24 h post-transfection, the cells were incubated with 25µg/ml CHX for 
different times (15 min to 6 h) and harvested for WB. ß-tubulin was used as a loading control 
(upper panels). Half-life was calculated based on WB bands intensities measured by the ImageJ 
software and evaluated following the gel analysis method outlined in the ImageJ documentation 
(lower panels). 
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Since no significant effect of the FLAG-tag positioning on degradation pattern of RINT1 
was observed (Fig. 11-12), the N-terminally FLAG-tagged protein version was applied for 
all subsequent experiments. 
 
3.1.2. RINT1 is degraded via proteasomal pathway 
Apart from investigating CHX influence on RINT1 cellular levels, protein stability was 
tested by the treatment of HEK293T cells transiently expressing FLAG-Rint1 plasmid with 
proteasome inhibitor, MG132. Interestingly, after 8h of the treatment, MG132 not only 
prevented RINT1 from degradation leading to significant protein accumulation, but a 
shifted-up band appeared, indicating putative post-translational modification (PTM) of 
the protein (Fig. 21, arrow indicates a “shifted-up band”). 
 
 
 
 
 
 
 
 
 
Figure 21. RINT1 is stabilized upon MG132 treatment. HEK293T cells expressing RINT1 were 
treated with 10 µM of proteasomal inhibitor MG132 for 0 h, 1 h and 8 h. Cells were harvested and 
analyzed by WB. ß-tubulin was used as a loading control. MG132 strongly stabilized RINT1 levels 
and 8 h of the treatment resulted in a shifted-up band. 
 
To delineate biological pathways involved in the regulation of RINT1 stability, RINT1-
transfected COS-7 cells were treated with or without addition of CHX with following 
agents: (i) leupeptin, an inhibitor of cysteine and trypsin-like proteases, (ii) ammonium 
chloride (NH4Cl) or (iii) chloroquine, inhibitors of lysosomal protein degradation and 
autophagy, (iv) rapamycin, an autophagy inducer, and (v) MG132, an inhibitor of 
proteasomal activity. Thus, three putative degradation pathways were tested: (1) 
lysosomal degradation pathway, (2) autophagy and (3) proteasomal degradation 
pathway. None of the (i-iv) treatments significantly affected RINT1 stability. All the 
chemicals were inefficient to block RINT1 degradation with an exception of MG132, which 
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clearly stabilized protein levels (Fig. 22). These results showed that RINT1 is degraded via 
a proteasomal pathway. 
 
Figure 22. RINT1 is degraded via proteasomal degradation pathway. COS-7 cells were 
electroporated with FLAG-Rint1 plasmid. At 24h post-electroporation, indicated chemicals were 
added: 12.5 µg/ml CHX, 5 mM NH4Cl, 0.2 µM rapamycin, 10 µM MG132, 25 µM chloroquine or 20 
µM leupeptin. After 8h of the treatment, cells were collected for WB analysis. ß-tubulin was used 
as a loading control. 
 
 
3.2. RINT1 ubiquitination 
Proteins degraded by the proteasome are usually modified by polyubiquitination 
(polyubiquitin, polyUb), a post-translational modification (PTMs) mediated by the activity 
of an E3 ligase. RINT1 was found to be degraded via proteasomal pathway, and the 
inhibition of proteasome activity resulted in the generation of an additional RINT1 form of 
higher molecular weight (“shifted-up band”) indicating a PTM. 
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3.2.1. RINT1 is polyubiquitinated 
To verify covalent attachment of polyUb chains to the RINT1 molecule, a co-
immunoprecipitation (co-IP)-mediated approach was applied. HEK293T cells were co-
transfected with plasmids harboring cDNA of human FLAG-tagged RINT1 and HA-tagged 
ubiquitin. 24 h after transfection, cells were treated with or without MG132 for 8 h, lysed 
and subjected to IP with either anti-FLAG or anti-HA antibodies. Immunoprecipitates were 
analyzed by WB (Fig. 23). 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. RINT1 is polyubiquitinated. HEK293T cells were co-transfected with indicated 
plasmids, treated or not with 10 µM MG132 for 8 h and lysed. Co-immunoprecipitates were 
subjected to WB analysis.  
 
In samples, in which RINT1 and ubiquitin were co-expressed, high molecular complexes 
were detected representing polyubiquitinated fraction of RINT1. The results clearly 
demonstrated, that RINT1 protein is modified by ubiquitination. 
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3.2.2. K48-linked polyubiquitin chains target RINT1 for proteasomal 
degradation 
Protein ubiquitination has different functions depending on which lysine (K) residue of 
ubiquitin is used as a polyUb chain linker. K48-mediated polyubiquitination is the most 
established as a mediator of proteasomal protein degradation. In K48-mediated 
polyubiquitin chain ubiquitin monomers are linked one to another via their lysine residue 
on the position 48. To define whether RINT1 ubiquitination is associated with protein 
degradation, FLAG-RINT1 was co-expressed in HEK293T cells together with plasmid 
encoding HA-tagged ubiquitin mutant, which lacked six out of seven lysines of ubiquitin 
aa sequence. All the lysines except lysine 48 were mutated to arginine (HA-Ub-K48). Thus, 
the detected ubiquitin chain could only be formed via the remained, non-mutated lysine. 
Co-IP-mediated analysis clearly confirmed that RINT1 was modified by K48-linked polyUb 
chains marking it for proteasomal degradation (Fig. 24). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. RINT1 is polyubiquitinated via K48- and K63-linked ubiquitin chains. HEK293T cells 
were co-transfected with indicated plasmids. Co-immunoprecipitates were subjected to WB 
analysis. 
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3.2.3. RINT1 is also polyubiquitinated by K29- and K63-linked chains 
The finding that RINT1 is markedly ubiquitinated with or without addition of MG132 (Fig. 
15), suggested the existence of additional ubiquitination modes of RINT1, besides the one 
mediated by K48 linkage. Thus, next experiments were designed to verify whether RINT1 
ubiquitination had only degradative functions, or other, related to signaling and/or 
regulation of protein functions. To answer this question, the series of co-IP experiments 
was performed. HEK293T cells were co-transfected with FLAG-RINT1 plasmid and HA-
tagged ubiquitin mutants: HA-Ub-K29, encoding ubiquitin with only one lysine residue on 
the position 29 (Fig. 25), or HA-Ub-K63 mutant, harboring ubiquitin with only K63 lysine 
residue (Fig. 24). All other lysines were mutated to arginine. In an analogous manner to 
previously described experiment, if RINT1-ubiquitin interaction was detected, it could 
only originate from the polyUb chains formed via K29- or K63-linkage. Cells were lysed, 
subjected to IP with either FLAG- or HA-antibody and analyzed by WB. The study revealed 
that RINT1 was also polyubiquitinated by K29- and K63-mediated polyUb chains, which 
are often addressed to have regulatory functions. 
 
IP results: 
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Input control:  
 
Figure. 25. RINT1 is polyubiquitinated via K29-linked ubiquitin chains. HEK293T cells were co-
transfected with indicated plasmids as described for Fig. 16. Co-immunoprecipitates were 
subjected to WB analysis. 
 
 
3.2.4. RINT1 is modified by mono- or linear ubiquitin chains 
Modification of a target protein function could also be achieved by attaching unbranched 
polyUb chain, which is a particular way of inter-ubiquitin linkage, called “head-to-tail” (or 
linear, or M1-linked) chain, leading to linear polyubiquitination. To investigate whether 
RINT1 could be subjected to this special way of ubiquitination, a co-IP experiment was 
performed, using lysine-less Ub mutant (Ub-K0), and FLAG-RINT1. Notably, in addition to 
forming linear polyUb chains, Ub-K0 might also attach to the target protein as a 
monomer, at one or multiple sites (monoubiquitination). Interestingly, RINT1 interacted 
covalently with Ub-K0 (Fig. 26), indicating linear ubiquitination of RINT1 and/or 
monoubiquitination. 
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IP results: 
 
 
 
 
 
 
 
 
 
 
 
Input control: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 26. RINT1 is polyubiquitinated via lysineless ubiquitin mutant. HEK293T cells were co-
transfected with indicated plasmids (as previously described for Fig. 16). Co-immunoprecipitates 
were subjected to WB analysis. 
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In conclusion, RINT1 was demonstrated to be polyubiquitinated not only by K48-polyUb 
chains, which target the protein for degradation, but also by K29-, K63-poluUb, and linear 
ubiquitin chains, or even monoubiquitination, at one or multiple sites, for regulatory 
and/or signaling purposes. To assay a relative abundance of the identified Ub linkages at 
the RINT1 protein, a co-transfection/co-IP experiment with all HA-Ub constructs 
previously applied (Fig. 23-26) and analyzed by detection with common antibodies was 
performed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. RINT1 is polyubiquitinated by K29-, K48-, K63- and K0 ubiquitin chains. HEK293T cells 
were co-transfected with indicated plasmids. Co-immunoprecipitates were subjected to WB 
analysis. 
 
The results shown in Figures 27 and 28 summarize all verified modes of ubiquitination of 
RINT1. Interestingly, as shown in Fig. 28, co-transfection of HEK293T cells with FLAG-
RINT1 and plasmids encoding HA-tagged non-mutated ubiquitin, or ubiquitin lysine 
mutants, resulted in relatively different RINT1-specific signal, depending on the ubiquitin 
mutant introduced to the cells. The strongest signal and clearly detectable ladder was 
observed in the case of co-transfection with HA-Ub-K29 and HA-Ub-K0 plasmids, 
suggesting a relative prevalence of these RINT1 modifications. 
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Figure 28. RINT1-specific signal intensity depends on the ubiquitin mutant interacting with 
RINT1. HEK293T cells were co-transfected with indicated plasmids. Lysates were subjected to WB 
analysis. ß-actin was used as a loading control. 
 
 
3.2.5. Screening for RINT1 interactors reveals protein candidates 
involved in ubiquitination 
In order to unravel the mechanism of RINT1 ubiquitination as well as a putative role of 
this process and possibly the function of the RINT1 itself, two screens, a yeast two-hybrid 
(Y2H) assay and mass spectrometry analysis, were performed. The specific objective of 
these screens was to identify proteins interacting with RINT1, especially E3 ubiquitin 
ligase(s), and mediating post-translational modifications. 
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3.2.5.1. Results of yeast two-hybrid screen 
Yeast two-hybrid screen was executed by Dr. Stefan Pusch, DKFZ, Heidelberg, Germany. It 
resulted in detection of several interesting candidates for RINT1-binding partners. The 
candidates were proteins related to introduction of ubiquitination or other post-
translation protein modifications. Following proteins, which fulfilled this requirement, 
were detected: 
 SUMO2 (small ubiquitin-related modifier 2), 
 PSME1 (proteasome activator complex subunit 1), 
 PKIA (cAMP-dependent protein kinase inhibitor alpha), 
 SENP8 (sentrin-specific protease 8 or NEDD8-specific protease 1), and 
 STK10 (serine/threonine protein kinase 10). 
Proteins listed above, indicated that RINT1 might be subjected to other PTMs, besides 
ubiquitination. In particular, detection of SUMO2 suggested a possibility of SUMOylation 
of RINT1, as SUMO protein is known to be involved in this process. Thus, SUMO2 was 
selected as promising candidate for further analysis and verification of the results of yeast 
two-hybrid assay. Of note, no E3 ubiquitin ligase was found by the screen procedure. 
 
3.2.5.2. Mass spectrometry analysis 
Next, mass spectrometry-mediated analysis was applied as another approach to detect 
binding partners of RINT1. In particular, the analysis was aimed at identification of 
proteins involved in PTM mediation and/or cellular pathways previously described as 
common with RINT1. HEK293T cells overexpressing GFP-tagged RINT1 were lysed and 
subjected to IP with GFP-binding alpaca antibody (having reduced background signal due 
to the lack of the light Ig light chains). In order to provide specificity for test, independent 
GFP-EV control analysis was included. Putative binding-partners were considered only 
when they were identified in the GFP-RINT1 pull down experiment and not in the GFP-EV 
one. Two independent screens were performed in cooperation with two core facility 
laboratories. SDS-PAGE gels containing immunoprecipitates were submitted for mass 
spectrometric analysis to the DKFZ Genomics and Proteomics Core Facility, and the ZMBH 
Core Facility for Mass Spectrometry (both Heidelberg, Germany). Similarly to the analysis 
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of the results of the yeast two-hybrid assay, proteins of interest were identified on the 
basis of possible engagement in mediation of PTMs as well as participation in cellular 
processes previously identified in the context of RINT1 function. In addition, they were 
verified for specificity of interaction using GFP-RINT1-transfected samples versus EV-GFP-
transfected control. The list of identified binding partners as well as examples of false-
positive results (e.g. CAND1_HUMAN) are shown in the table (Tab. VII). Partner proteins 
should be considered as a RINT1-specific interactors only if found in GFP-RINT1, and not 
in GFP-EV sample. The examples of false-positive results (e.g. CAND1_HUMAN) are shown 
in the table. 
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Conditions of mass spectrometry analysis 
 
Database: 
Database Name: the SwissProt_2013_07 database  
Taxonomy: Homo sapiens 
Number of Proteins: 20341 
 
Search Engine:  
Mascot, Version: 2.4.1 
Fragment Tolerance: 0,50 Da (Monoisotopic) 
Parent Tolerance: 100 PPM (Monoisotopic) 
Digestion Enzyme: Trypsin 
Max Missed Cleavages: 1 
Probability Model:  
X-13-150-03: Peptide Prophet with Delta Mass Correction [+2 and below,+3,+4,+5,+6 and above] 
X-13-150-04: Peptide Prophet with Delta Mass Correction [+2 and below,+3,+4,+5,+6 and above] 
X-13-150-05: Peptide Prophet with Delta Mass Correction [+2 and below,+3,+4,+5,+6 and above] 
X-13-150-06: Peptide Prophet with Delta Mass Correction [+1,+2,+3,+4,+5,+6 and above] 
X-13-150-07: Peptide Prophet with Delta Mass Correction [+2 and below,+3,+4,+5,+6,+7 and 
above] 
X-13-150-08: Peptide Prophet with Delta Mass Correction [+1,+2,+3,+4,+5,+6 and above] 
 
Scaffold Version:  
Scaffold_4.0.7 
Peptide Thresholds: 90% minimum 
Protein Thresholds: 90% minimum and 1 peptide minimum 
Peptide FDR: 1,9% (Prophet) 
Protein FDP: 1,9% (Prophet) 
 
 
Database search: Charge state deconvolution and deisotoping were not performed. All 
MS/MS samples were analyzed using Mascot (Matrix Science, London, UK; version 2.4.1). 
Mascot was set up to search the SwissProt_2013_07 database (selected for Homo 
sapiens, 20341 entries) assuming the digestion enzyme to be trypsin. Mascot was 
searched with a fragment ion mass tolerance of 0,50 Da and a parent ion tolerance of 100 
ppm. Carbamidomethyl of cysteine was specified in Mascot as a fixed modification. 
Deamidated of asparagine and glutamine, oxidation of methionine, phosphorylation of 
serine, threonine and tyrosine and GlyGly of lysine were specified in Mascot as variable 
modifications.  
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Criteria for protein identification: Scaffold (version Scaffold_4.0.7, Proteome Software 
Inc., Portland, OR) was used to validate MS/MS based peptide and protein identifications. 
Peptide identifications were accepted if they could be established at greater than 90,0% 
probability by the Peptide Prophet algorithm (Ramakrishnan, Vogel et al. 2009) with 
Scaffold delta-mass correction. Protein identifications were accepted if they could be 
established at greater than 90,0% probability and contained at least 1 identified peptide.  
Protein probabilities were assigned by the Protein Prophet algorithm (Nesvizhskii, Keller 
et al. 2003). Proteins that contained similar peptides and could not be differentiated 
based on MS/MS analysis alone were grouped to satisfy the principles of parsimony. 
 
In both experiments, HUWE1 E3 ubiquitin ligase was identified as a binding partner of 
RINT1. In addition, the analysis performed by the ZMBH core facility identified three other 
E3 ubiquitin ligases: RNF20 and RNF40, known to form a functional heterodimeric 
complex RNF20/40, and TRIM25 E3 ligase. Since TRIM25 was also identified in EV control-
transfected sample, this protein was not regarded as a specific interactor of RINT1. 
Interestingly, SUMO2 was also found to be a binding partner of RINT1 by one of the 
screens, which confirmed the result of the yeast two-hybrid assay. In consequence, the 
proteins: HUWE1, RNF20, RNF40 and SUMO2, were subjected to further tests in order to 
verify their binding to RINT1 and the role in RINT1 post-translational modifications. Of 
note, the analysis identified Xaa-Pro aminopeptidase 1 (XPP1) as RINT1 binding partner 
confirming its specificity, since this proteins was previously reported to be RINT1 
interaction-partner (source database: IntAct, (Stelzl, Worm et al. 2005)). 
 
3.2.6. HUWE1 and RNF20/40 interact with RINT1 
Since mass spectrometry analysis strongly suggested, that HUWE1 and RNF20/40 are E3 
ubiquitin ligases able to interact with RINT1, subsequent IP experiments were performed 
to confirm the relevance of these interactions.  
HEK293T cells were co-transfected to express GFP-tagged RINT1 and HA-tagged HUWE1 
or RNF40 proteins. EV (tag)-co-transfected cells were included into analysis to verify 
specificity of binding. The cellular lysates were subsequently subjected to GFP-mediated 
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IP. Then, the WB membranes were probed with anti-HA antibody. In the 
immunoprecipitates of RINT1, an interaction band(s) were observed (Fig. 29), indicating 
HUWE1-and RNF40-specific signals. No signal was detected for cells harboring GFP-EV 
control. Thus, interaction between RINT1 and HUWE1 and between RINT1 and RNF40, 
was confirmed. 
A       B 
 
 
 
 
 
 
 
 
Figure 29. HUWE1 and RNF40 E3 ubiquitin ligases interact with RINT1. A. HEK293T cells were co-
transfected with GFP-RINT1 and HA-tagged HUWE1. HUWE1 was identified in RINT1 
immunoprecipitate. B. HEK293T cells were co-transfected with GFP-RINT1 and HA-tagged RNF40. 
RNF40 was identified in RINT1 pull-down. 
 
To verify whether the observed interaction between RINT1 and HUWE1 is not tag-
dependent, and given a substrate promiscuity of HUWE1, a FLAG-RINT1 expression 
construct was used for additional IP experiment. The analysis was performed as described 
for GFP-tagged RINT1. Anti-FLAG antibody-mediated detection showed a clear HUWE1-
specific signal, and positively verified binding of HUWE1 to RINT1 (Fig. 30). RINT1 could 
not be detected in HUWE1 cell lysate pull-down (data not shown). This result could be 
explained by a low amount of total cellular HUWE1 protein interacting with RINT1, thus 
staying below detection limits even after pull-down. 
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Figure 30. HUWE1 E3 ubiquitin ligase interact with RINT1. HEK293T cells were co-transfected 
with FLAG-RINT1 and HA-tagged HUWE1. HUWE1 was identified in RINT1 immunoprecipitate.  
 
3.2.6.1. HUWE1 and RNF20/40 are RINT1 E3 ligases 
The co-IP analyses confirmed mass spectrometry results and binding RINT1 to HUWE1 
and RNF40 E3 ligases. To corroborate the function of HUWE1 and RNF20/40 complex in 
RINT1 degradation, the experiments involving shRNA-mediated depletion of ligases were 
performed. HEK293T cells were co-transfected with FLAG-RINT and the plasmids 
harboring shRNA against HUWE1-, RNF40- or RNF20-specific mRNA (respectively), to 
down-regulate E3 ligases expression. The plasmid encoding shRNA-scramble was included 
into study as an EV-control. 24 h after transfection, cells were lysed and subjected to WB 
analysis. To confirm the reduction of the cellular levels of E3 ligase upon overexpression 
of shRNA plasmid, membranes were probed with anti-HUWE1, anti-RNF40, or anti-RNF20 
antibodies, depending on the experiment and the specific shRNA plasmid used. 
Subsequently, WB membranes were probed with anti-FLAG antibody, to determine the 
impact of E3 ligase depletion on putative stabilization of RINT1. Anti-calnexin or anti-ß-
actin antibodies were used as loading controls. The experimental assumption was made 
that the knock-down of E3 ligase responsible for RINT1 polyubiquitination leading to 
protein degradation, could prevent the protein from proteasomal processing, thus 
resulting in stabilization of its cellular levels. Indeed, shRNA-mediated depletion of all 
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tested E3 ligases led to strong stabilization of RINT1, being a consequence of the 
inhibition of protein degradation (Fig. 31). The observed changes in protein levels were 
additionally quantified by densitometric analysis. In addition, in the case of HUWE1, 
knock-down was also confirmed at the mRNA level using reverse-transcription qRT-PCR 
(data not shown). 
 
A.                  B.     
 
 
 
 
 
 
C.          
 
 
 
 
 
 
Figure 31. HUWE1 and RNF20/40 E3 ligases regulate RINT1 stability. A. shRNA-mediated 
depletion of HUWE1 promotes stabilization of RINT1. B. shRNA-mediated depletion of RNF40 
promotes stabilization of RINT1. C. shRNA-mediated depletion of RNF20 promotes stabilization of 
RINT1. 
 
Interestingly, this effect was the most pronounced in the case of the RNF20 knock-down, 
since the minor reduction in the ubiquitin ligase protein level resulted in a high increase 
of RINT1-specific signal (Fig. 31C).  
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These experiments demonstrated the functional importance of revealed interactions 
between HUWE1, RNF20, RNF40 and RINT1, and showed that these ligases regulate 
RINT1 stability by targeting it towards proteasomal degradation pathway. 
 
3.2.7. Mapping ubiquitination sites of RINT1 
3.2.7.1. In silico analysis predicted several putative ubiquitination 
sites along RINT1 sequence 
In order to identify target sites within RINT1, which could be subjected to ubiquitination, 
the in silico prediction using the on-line available software was performed 
(www.ubpred.org and www.bdmpub.biocuckoo.org). The analysis revealed multiple, 
lysine residues, which could presumably be modified by ubiquitination, and assigned 
confidence (probability) of their occurrence (Fig. 32). Specifically, six lysine residues (K24, 
K29, K41, K108, K293, K578) were assigned high or medium confidence, while four lysine 
residues (K62, K114, K525, K771) were of low for possible regarding ubiquitination. 
 
 
 
 
Figure 32. RINT1 has multiple putative ubiquitination target sites. RINT1 lysine residues 
predicted to be a possible subject of ubiquitination. Colors mark the confidence of prediction: red 
= high confidence, blue = medium confidence, green = low confidence. 
 
3.2.7.2. Site-directed mutagenesis of major in silico predicted 
ubiquitination site does not affect polyubiquitination of 
RINT1 
Since lysine 24 (K24) was in silico predicted to be one of two major RINT1 residues 
probable to undergo ubiquitination (highest confidence score assigned together with 
residue K288), a site-directed mutagenesis approach was performed. RINT1 mutant 
protein where lysine on the position 24 was mutated to arginine was generated and 
designated “RINT1-K24R” (K to R mutation, FLAG-RINT1-c.71A>G). Positioning of the K24 
N C 
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residue near the beginning of the protein sequence (N terminus) and in the vicinity of 
several putative ubiquitination sites of lower probability, suggested its particular role. 
HEK293T cells were transfected to co-express FLAG-tagged RINT1 or RINT1-K24R proteins 
together with HA-tagged ubiquitin, and co-IP experiment was performed. Unfortunately, 
upon FLAG-mediated IPs against RINT1 or RINT1-K24R proteins, no difference in signal 
intensity for ubiquitin (HA-mediated ubiquitin detection) could be detected. No 
difference was also seen for FLAG-mediated RINT1 detection in case of HA-mediated IP 
against ubiquitin. This result strongly suggested a lack of major functional role of K24 site 
in the ubiquitination of RINT1 protein (Fig 33).  
 
 
 
 
 
 
 
 
 
 
 
Figure 33. RINT1 K24 is not of a major importance for RINT1 ubiquitination. HEK293T cells were 
co-transfected with indicated plasmids. Co-immunoprecipitates were subjected to WB analysis. 
 
Although this experiment did not entirely exclude a role for K24 residue in targeting 
RINT1 for degradation, the similarly high intensity of ubiquitination-specific signals for WT 
and K24R-mutated version of RINT1 indicated an existence of multiple active 
ubiquitination sites along RINT1 sequence. 
 
3.2.7.3. Truncated versions of RINT1 are stabilized upon proteasome 
inhibition 
In order to determine which region of RINT1 protein sequence is of a major importance 
for K48-mediated ubiquitination and subsequent protein degradation, several RINT1-
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truncated mutants were analyzed. The mutant constructs were as follows: (i) RINT1-N, N-
terminal part of the protein, 1-264 amino acids out of 792, (ii) RINT1-M, middle part of 
the protein, 200-585 amino acids, (iii) RINT1-C, C-terminal part of RINT1, 565-792 amino 
acids, (iv) RINT1-Δ1, lacking first 62 amino acids of RINT1, (v) RINT1-Δ2, 115-792 amino 
acids, and (vi) RINT1-Δ3, 294-792 amino acids (Fig. 34). Three generated RINT1 “Δ” 
truncated mutants lacked the three major groups of putative ubiquitination adjacent 
sites, as defined via in silico prediction).  
 
 
 
 
 
 
 
 
 
Figure 34. RINT1 truncated mutants are stabilized upon MG132 treatment. Scheme represent 
RINT1-truncated fragments (RINT1-N, RINT1-M, RINT1-C, RINT1-Δ1, RINT1-Δ2, RINT-Δ3) and 
shows MG132-stabilized parts of the protein. 
 
The constructs, encoding FLAG-tagged RINT1 truncated mutants, were introduced to 
HEK293T cells. 24 h after transfection MG132 or CHX were added to the cell culture, in 
order to inhibit proteasomal degradation or block protein translation, respectively. WB 
analysis showed that (1) all the expressed mutant proteins were stabilized upon MG132 
treatment, and (2) the level of mutant proteins decreased upon CHX treatment (Fig. 35). 
In addition, as previously reported for the wild-type protein, the protein levels of RINT1-
Δ1, RINT1-Δ2 and RINT1-Δ3 mutants were not only stabilized by MG132, but the 
C N 
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additional, shifted-up band was detected (Fig. 35, arrows), directly indicating their post-
translational modification. 
All of tested proteins were successfully expressed in the cells except one, FLAG-RINT1-C 
mutant, which signal could not be reliably detected despite several attempts. MG132 
treatment did not lead to the appearance of RINT1-C mutant-specific band, thus to the 
protein stabilization. Therefore, inability to detect this mutant seems not be related to 
rapid proteasome-mediated degradation, but rather to other mechanism leading to 
protein instability (other proteases, protein misfolding). 
Altogether, these findings indicated that RINT1 truncated mutants are degraded via 
proteasomal degradation pathway. Thus, the sequence of the expressed protein 
fragments include lysines residues tagged by ubiquitin for the degradation. Therefore, it 
indicates the existence of multiple ubiquitination sites within RINT1 protein, all leading to 
K48-mediated proteasomal decay. Moreover, in truncated mutants different 
ubiquitination sites might be active, thus having alternative function, i.e. substituting for 
each other. This observation suggests also an involvement of more than one E3 ubiquitin 
ligase, which is consistent with the previous results, and/or, of an E3 ligase of low 
substrate specificity for the recognition of protein sequences for K48-linkage anchoring. 
 
 
 
 
 
 
 
 
 
 
Results 
 
88 
 
A 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
Figure 35. RINT1 truncated mutants are degraded via proteasomal pathway. HEK293T cells were 
transfected with indicated RINT1-mutants and treated or not with 10 µM MG132 or 25 µg/ml 
CHX. A. RINT1-N and RINT1-M mutants are stabilized upon MG132 treatment and depleted upon 
CHX treatment. B. RINT1-Δ1, RINT1-Δ2, and RINT1-Δ3 mutants are stabilized upon MG132 
treatment and depleted upon CHX treatment. Additional “shifted-up” bands for higher molecular 
form of RINT1 are indicated with arrows. 
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3.3. RINT1 and SUMOylation 
The screens, originally intended to discover RINT1-binding partners related to the 
ubiquitination, revealed several other interesting proteins, potentially involved in 
different RINT1 post-translational modifications. SUMO2 protein was one of them, found 
independently as a RINT1 interaction partner in yeast two-hybrid assay, as well as in the 
mass spectrometry screen. 
 
3.3.1. Prediction of putative SUMOylation sites of RINT1 
As a first step in unraveling presumed RINT1 SUMOylation, in silico prediction of putative 
SUMO-target sites within RINT1 was performed. Software used (www.phosida.com, 
sumosp.biocuckoo.org/online.php) indicated two lysines, K449 and K525, as potentially 
capable of being modified by SUMO protein(s). 
Based on the position of the two sites identified, two mutant versions of RINT1 were 
generated by site-directed mutagenesis: RINT1-K449R (point mutation c.A1346G) and 
RINT1-K525R (point mutation c.1574G). HEK293T cells were transfected to transiently 
express FLAG-RINT1 WT, FLAG-RINT1-K449R or FLAG-RINT10K525R mutants, with HA-
SUMO1, HA-SUMO2 or EV-HA control. Subsequently, WB analysis of cellular lysates was 
performed. In the samples expressing FLAG-RINT1-K449R mutant together with HA-
tagged SUMO1 protein, the RINT1 FLAG-specific band appeared shifted up as compared 
with RINT1 WT co-transfected with EV-HA control (Fig. 36A). This effect was not observed 
in the sample co-expressing FLAG-RINT1-K525R mutant together with HA-SUMO1 (Fig. 
36B). This result suggested that lysine residue on the position 449 is not involved in the 
SUMOylation of RINT1, while K525 appears to be an active SUMO1-target site. In the case 
of experiments with co-expression of the HA-tagged SUMO2 protein, WBs were not 
conclusive. 
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A           B 
 
 
 
 
 
 
 
 
 
 
Figure 36. Putative SUMOylation of RINT1. HEK293T cells were co-transfected with indicated 
plasmids. A. RINT1-specific band in the sample co-transfected with FLAG-RINT1-K449R and HA-
SUMO1 was shifted-up to a higher molecular weight as compared to the control sample 
transfected with FLAG-RINT1 WT and EV-HA. K525 of RINT1 is potential SUMO-target residue. B. 
This effect was not observed in the case of lysates of the cells co-transfected with FLAG-RINT1-
K525R, indicating that K525 of RINT1 is a potential SUMO-target residue. 
 
3.3.2. Putative interaction of RINT1 with SUMO1 and SUMO2 
proteins 
To further verify, if RINT1 is a subject of SUMOylation several experimental approaches 
were applied. Results of these preliminary experiments indicated covalent modification of 
RINT1 by SUMO1 and/or SUMO2 proteins, however further optimization steps and 
independent repetitions are needed to definitely confirm this finding. 
HEK293T cells were transfected to co-express FLAG-RINT1 protein (or FLAG-EV control 
plasmid) together with HA-tagged SUMO1 or SUMO2 proteins. The samples were 
subsequently subjected to FLAG- or HA-mediated IP. The WB membranes were probed 
with anti-HA and anti-FLAG antibodies, respectively. In the samples expressing FLAG-
RINT1 and HA-SUMO1, a very weak signal for FLAG-specific band was detected (HA-
mediated IP), suggesting the putative interaction between FLAG-RINT1 and HA-SUMO1 
proteins. This band was not observed in the samples expressing FLAG-RINT1 and HA-
SUMO2 protein. Notably, the levels of over-expressed HA-SUMO2 protein were low as 
compared with HA-SUMO1 over-expression (data not shown). 
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To increase specificity of the detection, a GFP-directed IP approach, using anti-GFP alpaca 
antibody (low background noise due to high specificity and a lack of light chains), was 
applied. EGFP-RINT1 or EGFP-EV control plasmids were overexpressed in HEK293T cells. 
Next, IP with an anti-GFP-antibody, WB and probing for endogenous SUMO1/2 proteins 
with specific anti-SUMO1 and anti-SUMO2 antibodies was performed. As a result, 
SUMO2-specific signal was detected, in contrary to the lysates of EGFP-EV control-
transfected cells. Interestingly, no SUMO1-specific band was detected (data not shown).  
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4. Discussion 
4.1. Unstable proteins and their significance for cellular homeostasis 
Protein turnover, including intracellular degradation and changes in the protein dilution 
rate, controls many vital cellular processes, such as signal transduction pathways, cell 
cycle progression, transcription, differentiation, or apoptosis (Hershko and Ciechanover 
1998; Ciechanover, Orian et al. 2000; Glickman and Ciechanover 2002; Ciechanover 
2005). At the level of the individual protein, the half-life is extremely important, as it is 
fundamental for the metabolism and the communication between the cell and its 
external environment. Moreover, at the level of organism, protein turnover rate plays an 
important role in disease (Schwartz and Ciechanover 1999; Nakayama and Nakayama 
2006). For example, disturbance in protein half-life may cause cancer (e.g. 
neuroendocrine tumors as a consequence of increased turnover of succinate 
dehydrogenase) or neurodegeneration (e.g. during mice embryonic development due to 
extension of a half-life Hes7 transcription factor by 8 min) (Hirata, Bessho et al. 2004; 
Yang, Matro et al. 2012). 
 
Proteins vary widely in term of the lability. The proteins with the shortest lifespan exist 
only minutes (e.g. E. coli heat shock response protein sigma 32 has a half-life of 4 min, 
eukaryotic p53 tumor suppressor has a life of ~5-20 min, and c-myc proto-oncogene has a 
half-life of ~30 min), whereas others are highly stable and their half-life is measured in 
months or even years, in case of the proteins of certain postmitotic tissues (e.g. eye lens 
crystalline with a half-life of ~70 years or elastin with a half-life of ~80 years) (Ramsay, 
Evan et al. 1984; Grossman, Straus et al. 1987; Giaccia and Kastan 1998; Verzijl, DeGroot 
et al. 2000; D'Angelo, Raices et al. 2009; Savas, Toyama et al. 2012). The significance of 
short-lived proteins cannot be underestimated, as they are among the most substantial to 
the cell survival and have mainly regulatory functions. For example, rapid removal of 
cyclins and cyclin-dependent kinases (CDKs) as well as cell cycle regulators, such as p21, 
p53 or p73, provides means for cell cycle control and allows for quick response to the 
changes in the environment and adaptation to new conditions, therefore for maintenance 
of the cellular homeostasis. Short-lived proteins also contribute to the regulation of 
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biological clock and circadian rhythm (e.g. TOC1) (Glickman and Ciechanover 2002; 
Lecker, Goldberg et al. 2006; van der Lee, Lang et al. 2014). 
With only ~40 min of experimentally determined lifespan, RINT1 certainly belongs to the 
category of the proteins with a short half-life. It is probably this feature, which allows 
RINT1 to fulfill regulatory functions. This assumption is reflected by an involvement of 
RINT1 in multiple, apparently unrelated, cellular processes, such as cell cycle progression 
(Xiao, Liu et al. 2001), ER-Golgi trafficking (Hirose, Arasaki et al. 2004; Arasaki, Taniguchi 
et al. 2006; Lin, Liu et al. 2007; Sun, Shestakova et al. 2007; Arasaki, Takagi et al. 2013), 
telomere length maintenance (Kong, Meloni et al. 2006), or the potential oncogenic and 
tumor suppressor functions (Lin, Liu et al. 2007; Quayle, Chheda et al. 2012; Fan, Wang et 
al. 2014; Park, Tao et al. 2014). Thus, modulation of the RINT1 half-life might be of a great 
importance for the cell survival and overall cellular homeostasis.  
 
4.2. Post-translational modifications and their modulatory effects on 
protein functions 
By definition, post-translational modifications (PTMs) occur after the translation of a 
given protein from respective mRNA has been completed. PTMs could involve different 
chemical alterations, like covalent addition of functional groups to proteins (e.g. 
phosphorylation, acetylation, glycosylation, methylation) or small regulatory proteins 
(e.g. ubiquitination, SUMOylation, neddylation, ISGylation) or the proteolytic cleavage of 
certain regulatory protein subunits (e.g. activation of proteolytic function of caspases 
upon cleavage). By all these different means, PTMs highly increase functional diversity of 
proteins beyond this encoded by the genome, and are an actual driver of plasticity of the 
proteome in response to changing cellular needs. 
 
4.2.1. Putative roles of RINT1 ubiquitination in the context of known 
cellular functions of RINT1 
Ubiquitination is well known for its potent role in the degradation of proteins, as well as 
for its miscellaneous regulatory functions. Moreover, different modes of (poly)ubiquitin 
chain formation modulate the impact of this PTM on proteins and enhance functional 
Discussion 
 
94 
 
meaning of the ubiquitination itself. Therefore, it is of particular interest to discuss the 
current findings in the light of the already established cellular roles of RINT1. 
 
4.2.1.1. Degradative functions of RINT1 ubiquitination 
The experimental work clearly showed that RINT1 cellular levels are tightly regulated by 
ubiquitination. RINT1 is not only polyubiquitinated at different sites, but also by different 
inter-ubiquitin chain linkage types: K29-, K48-, K63- and K0 (as linear polyubiquitination 
and/or monoubiquitination). Depending on a particular lysine residue involved in the 
chain formation, ubiquitination of RINT1 may have different roles and different impact on 
protein functions. In that respect, K48-linked polyubiquitination, as a PTM which is best 
established for targeting proteins for 26S proteasomal degradation, could be of a major 
importance for the regulation of the protein half-life, since RINT1 depletion was 
completely blocked by MG132 treatment (Figs. 21 and 22). In addition, pharmacological 
modulation of lysosomal and autophagic protein degradation pathways had no significant 
effects on RINT1 stability (Fig. 22). 
In contrast to K48-mediated modification, functions of K29-, K63- and K0 ubiquitination 
are much more elusive. Since a role in the regulation of protein degradation by K63-, and 
to a lesser extent K0-/linear or K29-mediated ubiquitin linkages, appears to be mostly 
limited to autophagic or lysosomal processes, detection of these specific modifications on 
RINT1 protein, may indicate their other, non-degradative but rather modulatory roles 
(Kim, Hailey et al. 2008; Zotti, Uva et al. 2011; Shaid, Brandts et al. 2013; Zhang, Xu et al. 
2013). Nevertheless, some experimental evidence point also towards the K29-, 
monoubiquitination and linear polyubiquitination as possible promoters of the 
proteasomal protein degradation (Kirisako, Kamei et al. 2006; Boutet, Disatnik et al. 2007; 
Kravtsova-Ivantsiv, Cohen et al. 2009; Prakash, Inobe et al. 2009; Carvallo, Munoz et al. 
2010; Yin, Gui et al. 2010; Zhao and Ulrich 2010; Dammer, Na et al. 2011). Since this 
observation relates to eukaryotic cells as well as bacteria and considering the fact that the 
proteasome has the ability of recognizing very diverse ubiquitin(-chains)-derived signals 
(except K63-polyubiquitination), it is also possible that the RINT1 is directed to the 26S 
proteasome turnover not only by K48-, but also by other ubiquitin-linkage type(s) (Xu, 
Duong et al. 2009). 
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4.2.1.2. Non-degradative functions of RINT1 ubiquitination 
Ubiquitination serves not only for degradation of targeted proteins. It is also involved in 
the regulation of many other vital cellular processes and pathways. The canonically non-
degradative modes of ubiquitination, such as attachment of monoubiquitin as well as 
linear-(K0-), K29- and K63-mediated polyubiquitinations were found to be present at 
RINT1. These modifications are known to play a role in processes such as: DNA damage 
response and error-free post-replication repair, cell cycle progression, protein sorting, 
endocytosis, or in general, in signal transduction (Passmore and Barford 2004; Pickart and 
Eddins 2004; Huang and D'Andrea 2006; Mukhopadhyay and Riezman 2007; Clague and 
Urbe 2010; Ramadan and Meerang 2011; Mocciaro and Rape 2012). 
Therefore, considering the many different cellular roles of the above mentioned 
ubiquitination modes (K29-, K63-, linear- and monoubiquitination), it is tempting to 
speculate that participation of RINT1 in a DNA damage-induced G2/M cell cycle arrest, as 
well as in the ER-Golgi trafficking, could be modulated by non-degradative poly- and/or 
multiple monoubiquitination. The involvement of RINT1 in such spatially and temporally 
separated processes (Xiao, Liu et al. 2001; Hirose, Arasaki et al. 2004; Sun, Shestakova et 
al. 2007; Aoki, Ichimura et al. 2009; Schmitt 2010), suggests the necessity of altering its 
cellular location and interaction with different protein binding partners, which could be 
achieved by such versatile post-translational modification as ubiquitination. 
One of the examples of modulatory effect of polyubiquitination on the protein function is 
its ability to change protein conformation. The attachment of ubiquitin molecules 
modifies structure of the target protein and precisely regulates formation of different 
protein complexes, thus affects protein activity in a specific time and compartment within 
the cell. The control of protein-protein interactions may be executed by modifications 
identified for RINT1, in particular K63-, but also K29-linked polyubiquitin chains (Passmore 
and Barford 2004; Wang, Gao et al. 2012; Shembade and Harhaj 2015). The structural 
protein modification may result not only from the coupling of multiple ubiquitins, but also 
from the single molecule of Ub appended to the substrate (monoubiquitination), which 
subsequently attaches to a ubiquitin-binding domain (UBD) of the same protein (Schnell 
and Hicke 2003). The detection of the covalent interaction-pattern between Ub-K0 
mutant and RINT1 protein in the co-immunoprecipitation experiments (Fig. 26) suggests 
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linear polyubiquitination, but also multiple monoubiquitination of RINT1. It is thus very 
likely that the supposed monoubiquitination of RINT1 serves as a modifier of a protein 
structure, leading to augmentation of RINT1 binding-partners spectrum.  
Still, modulation of protein conformation might not be the sole function of RINT1 
monoubiquitination. This kind of post-translational modification is, in general, 
characteristic for proteins involved in the membrane protein trafficking (Rotin, Staub et 
al. 2000; Katzmann, Odorizzi et al. 2002), a cellular process in which RINT1 was found to 
play an important role (Hirose, Arasaki et al. 2004; Arasaki, Taniguchi et al. 2006; Arasaki, 
Takagi et al. 2013).  
Monoubiquitination is known to be an essential and at the same time sufficient endocytic 
signal for the proteins located on the surface of the cell (Shih, Sloper-Mould et al. 2000; 
Haglund, Sigismund et al. 2003), as well as for the sorting of transmembrane proteins. 
However, its modulatory role in case of the involvement of RINT1 in the membrane 
trafficking might be more indirect. Some of the proteins incorporated to the cell and 
sorted in an ubiquitin-dependent process are not modified by Ub, but need to interplay 
with an intermediary protein-factor, which regulates their transport and is itself subjected 
to monoubiquitination. For example epsins, proteins involved in endocytosis and 
participating in the formation of clathrin-coated vesicles, contain ubiquitin-interacting 
motifs (UIMs), which bind monoUb prior to the internalization of receptors at the plasma 
membrane. Another example is Vps27p protein from Saccharomyces cerevisiae. Like 
epsins, it interacts with monoUb through its UIM and this interaction is essential for 
endosomal cargo sorting (Myat, Henry et al. 2002; Shih, Katzmann et al. 2002; Schnell and 
Hicke 2003). It is thus possible, that the presumed multiple monoubiquitination of RINT1 
is a necessary signal allowing RINT1 to act as such an intermediary protein factor for the 
efficient and accurate inter-membrane transport of other proteins and, in consequence, 
changes their intracellular localization.  
Another putative role of monoubiquitination of RINT1 is related to its function in the 
process of the DNA repair (Xiao, Liu et al. 2001). In order to properly correct genetic 
material, accurate recruitment of proteins constituting DNA repair machinery to the spot 
where DNA damage occurred, is essential. The signal for translocation might be provided 
by monoubiquitination. Such mechanism was described for the Fanconi anemia protein 
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(FANCD2), which is targeted to the nuclear foci and co-localizes with BRCA1 upon 
monoubiquitination in the S phase of the cell cycle (Garcia-Higuera, Taniguchi et al. 2001; 
Gregory, Taniguchi et al. 2003; Nakanishi, Yang et al. 2005). It is quite likely, that the co-
localization of RINT1 with RAD50, and their acting in the process of the radiation-induced 
G2/M cell cycle checkpoint, is driven by (mono)ubiquitination of the protein(s). To 
provide more information on this topic, it would be interesting to investigate RINT1 
monoubiquitination in the context of various DNA-damage triggers and in different stages 
of the cell cycle. It should be stressed, that hypothetically monoubiquitination of RINT1 
might steer both binding to different interaction-partners, and, at the same time, its 
intracellular location during the specific stage of the cell cycle. 
Linear attachment of ubiquitin molecules by polyUb K0-linkage is yet another, and 
importantly, rarely occurring non-degradative mode of ubiquitination, which was found 
to be mediated by the Linear Ubiquitin Chain Assembly Complex (LUBAC). Interestingly, 
current experimental work identified K0-mediated Ub linkages at the RINT1 protein, 
which could be indicative of linear polyubiquitination. Moreover, LUBAC is recognized as a 
major player in signaling pathways crucial for innate and adaptive immunity (Rieser, 
Cordier et al. 2013), such as TNFR1-induced signaling during inflammatory response. 
Although there is yet no evidence of RINT1 participation in the immunity-related signaling 
pathways, bearing in mind functions of linear ubiquitination and the fact, that this 
modification potentially affects RINT1, it is suggestive to investigate a putative role of 
RINT1 in the immune system. To this end, high levels of RINT1 transcripts detected in T 
and B cells of mice are of potential interest (according to BioGPS database search, 
www.biogps.org). 
 
4.2.2. Characteristics and functions of HUWE1 and RNF20/40 in 
relation to known functions of RINT1 
The alignment of amino acid sequences of stabilized RINT1 fragments strongly suggested 
the existence of more than one ubiquitin-binding site within RINT1 protein, as well as 
presumably, more than one E3 ligase targeting RINT1 for the proteasomal degradation. 
Indeed, mass spectrometry analysis of RINT1 immunoprecipitates identified two E3 
ligases, HUWE1 and RNF20/40 complex, as RINT1 binding partners. Subsequently, series 
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of co-immunoprecipitation experiments confirmed these interactions (Fig. 29-30). The 
current study has shown that both enzymes regulate RINT1 stability (Fig. 31), which is in 
line with the previous reports describing them as crucial modulators of protein levels. On 
the one hand, HUWE1 polyubiquitinates and targets for the proteasomal degradation 
such important proteins as: major anti-apoptotic regulator Mcl1 (Zhong, Gao et al. 2005), 
tumor suppressor BRCA1 (Wang, Lu et al. 2014), proto-oncogenes N-Myc and c-Myc 
(Zhao, Heng et al. 2008) or developmental master regulator MyoD (Noy, Suad et al. 2012). 
On the other hand, the RNF20/40 complex acts as a proteasomal-degradation promoter 
of Syntaxin 1, a major component of exocytosis membrane fusion machinery (Chin, 
Vavalle et al. 2002), a transcription factor AP-2α (Ren, Sheng et al. 2013), and of p42 
isoform of tumor supressor Ebp1 (Liu, Oh et al. 2009).  
However, both ligases are known to have not only degradative, but also regulatory impact 
on their targets. This is possible through their capability to form ubiquitin chains other 
than mediated by K48-inter-ubiquitin linkages. For example, HUWE1 was found to 
catalyze formation of the K63-ubiquitin poly-chains at the c-Myc protein (Adhikary, 
Marinoni et al. 2005). Moreover, both HUWE1 and RNF20/40 are able to 
monoubiquitinate their substrates: HUWE1 modifies DNA polymerase ß (Parsons, Tait et 
al. 2009), while RNF20/40 complex is responsible for monoubiquitination of histone H2B 
(Zhu, Zheng et al. 2005). The above-mentioned different modes of the ubiquitination 
catalyzed by HUWE1 and RNF20/40, suggest that K63- and/or putative multiple 
monoubiquitination of RINT1 might be triggered by HUWE1 and RNF20/40 E3 ubiquitin 
ligases in addition to their primarily role as modulators of stability, and thus cellular levels 
of RINT1 protein. 
While it is relatively common, that a given protein interacts with, and is modified by more 
than one E3 ubiquitin ligase, it remains very often challenging to determine the cellular 
function of the introduced ubiquitin chains. Strikingly, both newly identified RINT1 
interactors, HUWE1 and RNF20/40 complex, intersect with RINT1 regarding their 
participation in common cellular processes. For instance, both HUWE1 and RNF20/40 
ligases modify substrates crucial for the cell cycle arrest, DNA repair, genome stability and 
tumorigenesis. 
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4.2.2.1. Role of HUWE1 in the context of cellular functions of  RINT1 
The first literature report regarding RINT1 addressed its role as a protein interacting with 
RAD50, thus involved in the G2/M cell cycle checkpoint activation, upon the irradiation-
induced DNA damage (Xiao, Liu et al. 2001). It is not yet known which mechanisms 
regulate RINT1 activation or function in this process. Presumably, certain post-
translational modifications, such as the ubiquitination, might play a modulatory or 
triggering role. HUWE1 is known to control the DNA repair pathway by 
monoubiquitinating and, in turn, regulating steady-state levels of the DNA polymerase ß, 
one of the crucial enzymes for the base excision repair (BER) pathway (Parsons, Tait et al. 
2009). However, in the context of an established RINT1 function in ensuring proper 
genomic integrity (Xiao, Liu et al. 2001; Lin, Liu et al. 2007; Park, Tao et al. 2014), the role 
of HUWE1 might be more indirect. For instance, both modifications identified for RINT1, 
putative monoubiquitination at multiple sites, as well as K63-polyubiquitination, might 
potentially control the recruitment of RINT1 to RAD50, and favor this interaction over 
others. Importantly, as mentioned before, both modes of ubiquitination are known to be 
catalyzed by HUWE1 E3 ubiquitin ligase (Zhao, Heng et al. 2008; de Groot, Ganji et al. 
2014; Jang, Shi et al. 2014). It is worth noting, that HUWE1 also regulates cellular 
functions of other proteins involved in the cell cycle checkpoint triggering and DNA repair 
signaling, such as p53, Cdc6, BRCA1 or TopBP1 (Hall, Kow et al. 2007; Herold, Hock et al. 
2008; Peter, Bultinck et al. 2014; Wang, Lu et al. 2014). Hereby, the regulation is achieved 
by modulating protein levels via targeting for proteasomal degradation. 
Correspondingly, one of the best described functions of HUWE1 is its involvement in the 
regulation of the extracellular signal-regulated kinase 1/2 (ERK1/2) pathway, by 
controlling levels of Shoc2 scaffold complex and the Raf-1 protein (Jang, Shi et al. 2014). It 
is another example of significant, regulatory role of HUWE1 ligase, resulting from assuring 
appropriate cellular levels of the proteins which are the key-players in the specific 
signaling pathways. Similarly, by targeting RINT1 for the 26S proteasomal degradation, 
HUWE1 contributes to the regulation of all the downstream processes demanding RINT1 
functional activity. 
HUWE1 was also found to act as a modulator of the dishevelled protein Dvl, hereby being 
involved in the Wnt/ß-catenin canonical signaling pathway. Interestingly, in this case 
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regulatory role of the E3 ubiquitin ligase is linked to the formation of K63-polyubiquitin 
chains and the negative feedback loop (de Groot, Ganji et al. 2014). Modification of Dvl by 
HUWE1 inhibits its multimerization, which is indispensable for the protein acting in the 
cell proliferation, segmentation and in the neuroblast specification. The K63-mediated 
polyubiquitination of Dvl illustrates how HUWE1 may influence protein function by 
modifying its spatial structure, thus capability of complex formation. Further research 
would answer the question, whether this mechanism of HUWE1 action is applicable to 
the RINT1 protein. 
Another link between known functions of RINT1 and HUWE1 is their tumor supressor 
activity. It was shown, that RINT1-depleted cells exhibit abnormalities during the cell 
division (Arasaki, Taniguchi et al. 2006), and the inactivation and subsequent 
heterozygous loss of Rint1 gene led to tumor formation in animal model (Lin, Liu et al. 
2007). Moreover, recent exome sequencing studies of breast cancer patients supported 
role of RINT1 as a tumor suppressor protein (Park, Tao et al. 2014). However, it is not 
recognized yet what kind of mechanisms underlie and provide this function for the RINT1 
protein. It is very likely, that one of the several currently reported modes of RINT1 
ubiquitination: K29-, K63-, and/or mono-/linear-ubiquitination, are driving its 
oncosuppresor activity. However, it is of course also possible, that HUWE1 provides this 
function of RINT1 simply by tagging it for the proteasomal degradation (K48-linked Ub 
chains) and acting as a regulator of RINT1 cellular levels. Such a mechanism was already 
described for another HUWE1 target, transcription factor and potent tumor suppressor 
Ebp1 (Liu, Oh et al. 2009). 
Last but not least, both HUWE1 and RINT1 are strongly involved in maintaining correct 
cell proliferation and differentiation programs, thus cellular homeostasis. As a E3 
ubiquitin ligase polyubiquitinating and leading to the degradation of p53 molecule and 
many other substrates like Myc, ARF, PP5, or Mcl-1 proteins, HUWE1 is one of the key 
regulators of apoptosis. The control of cellular levels for listed proteins, imply HUWE1 
function in neural differentiation, proliferation, as well as in the development and growth 
of Myc-driven solid tumors (Adhikary, Marinoni et al. 2005; Chen, Kon et al. 2005; Zhong, 
Gao et al. 2005; Kurokawa, Kim et al. 2013). It is therefore possible, that the in vivo tumor 
formation observed for primary murine astrocytes overexpressing RINT1 (Quayle, Chheda 
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et al. 2012) is caused by overriding the control mechanism provided by HUWE1 E3 
ubiquitin ligase with excessive amounts of overexpressed RINT1 protein, which under 
normal conditions would lead to effective removal of ubiquitinated RINT1. 
 
4.2.2.2. Role of RNF20/40 vs. RINT1 functions 
RNF20/40 E3 ubiquitin ligase is well known for its functions regarding the gene regulation 
and transcriptional activation as well as for its potent role in the DNA damage response 
and the cell cycle progression.  
By selective regulation of gene expression, RNF20/40 was found to act as a putative 
tumor suppressor (Kim, Hake et al. 2005; Shema, Tirosh et al. 2008). This function is 
mostly associated with the histone monoubiquitination by RNF20, and resulting changes 
in the gene expression pattern (Kim, Hake et al. 2005; Zhu, Zheng et al. 2005; Kim, 
Guermah et al. 2009). Nevertheless, RNF20/40 complex acts also as a factor inhibiting 
tumor suppressive activity by polyubiquitinating and tagging for the proteasomal 
degradation isoform 2 of PA2G4 protein in cancer cells (Liu, Oh et al. 2009). Interestingly, 
RINT1 was described as a both tumor suppressor (Lin, Liu et al. 2007; Park, Tao et al. 
2014) and oncogene (Quayle, Chheda et al. 2012; Fan, Wang et al. 2014). Thus, it is 
tempting to hypothesize, that RNF20/40 might be the key regulator of the RINT1 activity 
in the tumor formation: either by its monoubiquitination, or by regulating cellular levels 
of the RINT1 protein. 
Another process, in which RNF20/40 ubiquitin ligase plays a significant role, is the 
regulation of the DNA repair by homologous recombination (HR). RNF20 is localized at the 
sites of double-stranded breaks (DSBs) and required for the DSB-induced 
monoubiquitination of histone H2B. Interestingly, the repair pathway involving RNF20 is 
not depend on H2AX, but associated with NBS1. Moreover, RNF20 activity seems to be a 
prerequisite for the accumulation of DNA repair proteins like BRCA1 and RAD51 at the 
sites of damage (Nakamura, Kato et al. 2011). Summarizing, RNF20/40 E3 ubiquitin ligase 
was found to have potent roles in the HR repair and in cell cycle checkpoint response to 
the irradiation-induced DNA damage. This is particularly interesting in the context of 
known roles of RINT1 in the DNA repair and in G2/M cell cycle checkpoint upon 
irradiation, as well as RINT1 interaction with RAD50 protein (Xiao, Liu et al. 2001). 
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Moreover, RAD50 plays a central role in the DSB repair and is a part of the MRN complex, 
which apart from RAD50 consists also of MRE11 and NBS1 proteins. Interestingly, MRE11 
and NBS1 are recruited to the DSBs by RNF20. This strongly suggests that RINT1, being a 
RAD50 interactor and itself ubiquitinated by RNF20/40 complex, can undergo the same 
mode of regulation for its recruitment to the MRN complex upon DNA damage-induced 
checkpoint control at the G2/M stage of the cell cycle. Therefore, the interaction between 
RINT1 and RAD50, as well as function of RINT1 in the DNA repair pathway might be driven 
by the activity of RNF20/40 ligase. 
 
4.2.3. A role of SUMOylation as possible modulator of known 
functions of RINT1 
SUMO protein was identified as the binding-partners of the RINT1 protein using both, the 
yeast two-hybrid assay and mass spectrometry screens. The interaction between RINT1 
and SUMO molecules was also suggested by preliminary co-immunoprecipitation 
experiments. These results indicate existence of yet another, besides ubiquitination, post-
translational modification of RINT1. The exact role of SUMOylation of RINT1 is to be 
discovered. However, knowing the crucial role of SUMO proteins in divergent cellular 
pathways, some assumptions of the impact of SUMOylation on RINT1 function could be 
made.  
Many described SUMO targets are transcription factors or proteins with general ability to 
influence gene expression (Wilson and Heaton 2008) and/or located in the nucleus. 
Therefore, SUMOylation is classically viewed as a major regulator of nuclear function. This 
overlaps with the observation, that apart from well-described cytosolic and membrane 
localizations of RINT1, the protein was additionally confirmed to be localized within the 
nucleus (Dr. P. Grigaravičius, unpublished data of our laboratory) corresponding with 
RINT1 function in regulation of DNA damage-induced cell cycle checkpoint as well as in 
telomere length maintenance (Xiao, Liu et al. 2001; Kong, Meloni et al. 2006). 
Nevertheless, more recent studies refer to SUMOylation as a possible modifier of the 
extra-nuclear proteins as well and regulator of very diverse cellular processes (Wasik and 
Filipek 2014). Similarly to the interaction between RINT1 and ubiquitin, functional 
importance of interaction between RINT1 and SUMO proteins could be crucial for 
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maintenance of cellular homeostasis. This may be predicted on the basis of common 
participation of RINT1 and SUMO1/2 in cellular processes as important as cell cycle 
progression, cell cycle checkpoint regulation, DNA damage repair and membrane 
trafficking (Sarangi and Zhao 2015). For RINT1, binding of SUMO to one or more lysine(s) 
might potentially modulate protein activity, subcellular localization or even stability 
(Geiss-Friedlander and Melchior 2007; Yang and Paschen 2009).  
In general, SUMOylation has a great impact on the DNA repair, for example it was shown, 
that SUMO proteins accumulate at DNA DSBs (Galanty, Belotserkovskaya et al. 2009; 
Morris, Boutell et al. 2009; Shima, Suzuki et al. 2013). In the course of DNA damage 
response (DDR), the role of SUMO manifests itself by the multilevel modulation of its 
target proteins. To this end, SUMOylation could be of potential, functional importance 
regarding involvement of RINT1 in DDR pathway as a binding partner of RAD50.  
SUMOylation plays also a crucial role in carcinogenesis, e.g. of prostate cancer or breast 
cancer, by regulating functions of key tumor suppressors and oncogenes such as p53 
(indirectly, via E3 ubiquitin ligase MDM2) or PTEN (Kim and Baek 2006; Geiss-Friedlander 
and Melchior 2007; Alshareeda, Negm et al. 2014; Chen and Lu 2015). Through its impact 
on genome stability, gene expression and protein-protein interactions, SUMOylation is 
also important for etiology of other human diseases, such as neuronal dysfunctions (e.g. 
Alzheimer’s, Parkinson’s and Huntington’s diseases) (Zhao 2007; Sarge and Park-Sarge 
2009; Yang and Chiang 2013; Henley, Craig et al. 2014). It is worth mentioning, that 
studies reporting the crosstalk between ubiquitination and SUMOylation exist (Papouli, 
Chen et al. 2005; Hunter and Sun 2008; Zhao, Brickner et al. 2014). In addition, possibility 
of targeting the same protein at one time by both ubiquitin and SUMO proteins was also 
reported (Lu, Liu et al. 2015). Moreover, it is also possible, that the same lysine residue 
within the same protein might be a target for both modifiers, and as a consequence, they 
might compete for the same site within the protein. Such mechanisms allow for 
modulating cellular functions (Chen and Lu 2015). It is thus reasonable to speculate that 
RINT1, as a tumor suppressor and an oncogene, might be subjected to this double 
modification and complex regulatory mechanism. However, further studies are required 
to support this hypothesis. 
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4.3. Conclusions and perspectives 
Experimental evidence presented in this work describes biochemical characteristics of the 
RINT1 protein, a novel oncogene and a tumor suppressor. Since RINT1 is a multifunctional 
protein involved in very diverse and crucial cellular pathways, and is indispensable for 
maintaining the cellular homeostasis, the information about its half-life and the mode of 
degradation may have broad implications and be the basis to disclose mechanisms 
governing modulation of its activity. Identification of ubiquitination and putative 
SUMOylation as two post-translational modifications affecting the RINT1 protein, as well 
as the novel finding that two E3 ubiquitin ligases modify RINT1, would potentially allow to 
design therapeutic strategy for the treatment of RINT1-related diseases, such as 
glioblastoma, breast cancer and Lynch syndrome cancers (Quayle, Chheda et al. 2012; 
Park, Tao et al. 2014). Nevertheless, it remains to be shown whether and how the 
reported RINT1 functions, like G2/M cell cycle checkpoint regulation, membrane 
trafficking and putative tumor suppression, could be modulated by HUWE1 and RNF20/40 
complex, novel binding partners reported in the present study. 
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8. Appendix 
8.1. The impact of RINT1 on the cell cycle and cell death in mouse 
embryonic fibroblasts (MEFs) 
It has been previously reported, that RINT1 could be involved in the regulation of cell 
cycle G2/M checkpoint (Xiao, Liu et al. 2001). Thus, to assay the effects of RINT1-
deficiency on cellular fate, two different mouse embryonic fibroblasts (MEFs) cell lines, 
POF35-5 and POF39-4, harboring inducible Rint1 genetic knockout under control of 4-
hydroxytamoxifen (4-OHT)-driven Cre recombinase were used. In addition, for each of the 
cell line, an EV control cell line, which did not express Cre recombinase (without 
possibility to knockout the Rint1 gene) was applied. In all experiments, cells were treated 
with 4-OHT for 0, 2 and 4 days. PCR analysis was performed to confirm the efficiency of 
Rint1 knock-out. 
 
8.1.1. Rint1-deficiency potentially leads to the cell cycle arrest of 
MEF cells 
To test the effects of 4-OHT-induced Rint1 knock-out on the cell cycle, two MEFs cell lines 
were used and the cell cycle profile was assayed using propidium iodide (PI) staining and 
the classical fluorescence-activated cell sorting (FACS)-mediated analysis. The results 
showed a possible block of the cell cycle in the G2/M phase of the cell cycle (in the case of  
POF39-4 cell line), when compared with the respective EV control line. The conclusions 
were drawn on the basis of event frequency (%) using FACS gating, however, further 
analysis by e.g. BrdU/PI staining or WB are needed to confirm this observation. 
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Figure A-1. Cell cycle analysis suggests block in G1/M phase upon Rint1 knock-out. 
Control cells (POF39-4 EV) or RINT1 KO cells (POF39-4 CER) were treated with 4-OHT for 4 
days. Results of representative experiment are presented.  
 
8.1.2. Rint1-deficiency leads to cell death of MEF cells 
To measure possibility of cell death induction upon Rint1 knock-out, a FACS-based 
measurement of membrane integrity loss monitored by PI uptake was applied (as 
described in the “Materials and methods” section). The experiments clearly showed, that 
Rint1 deficiency (upon 2 or 4 days of CRE-induced recombination) leads to an increased 
cell death in both cell lines investigated, as compared with the respective 4-OHT-treated 
EV control cell lines (regardless of a mild toxic effect ascribed to 4-OHT alone observed for 
EV control cell lines). Cell death observed at day 4th upon the 4-OHT treatment was more 
pronounced than after 2 days of the treatment. To compare the observed effects 
between different cell lines, a “specific cell death” (%) index was calculated, described in 
“Materials and Methods” section (cell death was normalized to the one observed for non-
4-OHT-treated controls). In conclusion, Rint1 protein was found to be essential for the 
survival of MEFs cells, since its knockout results in cell death. 
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Figure A-2. Cell death induced by RINT1 knock-out. Cells were treated with 4-OHT for 4 
days. Average values of duplicated measurements are presented. 
 
 
8.1.3. Analysis of cell apoptosis-induced nuclear fragmentation 
Intra-nucleosomal fragmentation of the genomic DNA and subsequent formation of 
characteristic nuclear fragments (so-called “subG1” population on the cell cycle diagram), 
constitute major features of the apoptotic cell death. Thus, to further characterize cell 
death process observed upon the Rint1 knock-out, analysis of nuclear fragmentation was 
performed. 
 
8.1.3.1. Microscopic analysis of DAPI staining 
4-OHT treatment of MEFs cell lines was performed in order to knock-out Rint1 (for 4 
days). Subsequently, cells were stained with DNA-intercalating dye DAPI and examined by 
fluorescence microscopy. Microscopic analysis demonstrated that no morphological 
changes characteristic for apoptotic fragmentation of the nuclei were detected in POF35-
5 or POF39-4 4-OHT-treated cells (data not shown). 
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8.1.3.2. FACS-mediated analysis of nuclear fragmentation 
The classical method of apoptotic nuclear fragmentation described by Nicoletti et. al., 
(Nicoletti, Migliorati et al. 1991) uses FACS to detect an apoptosis-specific subG1 
population of nuclear fragments (see “Materials and Methods” section). Although 
marginal increase in (%) of subG1 population was observed (2-5%) upon the 4-OHT 
treatment alone (2 and 4 days), it was not Rint1 related, since the same effect was 
observed for EV control cell lines. 
 
 
 
 
 
 
 
 
 
 
Figure A-3. Rint1 knock-out-induced cell death is not characterized by apoptotic nuclear 
fragmentation. Control cells (POF39-4 EV) or Rint1 KO cells (POF39-4 CER) were treated 
with 4-OHT for 4 days. Results of representative experiment are presented. 
 
 
8.1.3.3. TUNEL test 
Apoptosis-induced intranucleosomal fragmentation of chromatin can be detected by 
terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) test (see “Materials 
and Methods” section for details). Both CRE MEF cell lines (POF35-5 and POF39-4), as well 
as EV control lines were treated for 0, 2 and 4 days with 4-OHT, to knock-out Rint1. Next, 
cells were stained using commercially available TUNEL kit, and fluorescence microscopic 
analysis was performed. The results did not show any significant apoptosis-related DNA 
damage in none of the investigated samples. 
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8.1.3.4. WB analysis of activation of apoptotic and DNA damage 
response signaling pathways upon Rint1 knock-out 
8.1.3.4.1. Apoptosis-related cleavage of poly (ADP-ribose) 
polymerase-1 (PARP) protein 
Generation of a cleaved form of PARP1 by activated Caspase-3 protein belongs to the late 
signaling events in an apoptotic process. Cells, in which Rint1 knock-out was induced 
upon the 4-OHT treatment (POF35-5 and POF39-4 cell lines; CRE and EV controls) were 
lysed and subjected to WB analysis. Membranes were probed with anti-PARP1 antibody. 
No cleaved form of PARP1, indicative for the apoptotic type of cell death was observed 
upon RINT1 depletion (Fig. A-4). However, clear caspase-induced PARP1 cleavage was 
observed in POF39-4 cell line upon control treatment with  etoposide (10 µM, 8 h), a 
classical apoptotic inducer. Similarly, no cleavage of caspase 3 could be detected in the 
cells dying upon Rint1 knock-out, additionally indicating a lack of activation of the 
apoptotic pathway, i.e. proteolytic activation of caspase 3 constitutes a necessary step in 
apoptosis. 
 
 
 
 
 
 
 
Figure A-4. Rint1 knock-out-induced cell death does not lead to PARP1 cleavage. Black 
arrow marks cleaved form of PARP1 in positive control sample treated with etoposide.  
 
 
8.1.3.5. DNA damage-induced expression of GADD153 
RINT1 is an interaction partner of Rad50, a protein involved in DNA double-strand break 
repair. Thus, activation of the DNA damage response upon Rint1 knock-out was 
investigated. GADD153 (CHOP10) is known as a growth arrest- and DNA damage-inducible 
gene. However, GADD153 was also postulated to play a role in the ER stress-mediated 
anti-PARP1 
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apoptosis pathway (Fornace, Nebert et al. 1989; Luethy, Fargnoli et al. 1990; McCullough, 
Martindale et al. 2001; Oyadomari and Mori 2004). 
POF39-4 MEFs CRE and EV cell lines were treated with 4-OHT for 0, 2 and 4 days. 
Subsequently, WB analysis was performed. Membranes were probed with anti-GADD153 
antibody. As a result, in POF39-4-CRE cells, treated with 4-OHT, a time-dependent 
accumulation of GADD153 protein was observed, which suggests an activation of DNA 
damage response upon Rint1 knock-out (data not shown). 
 
In conclusion, the observed cell death mode in MEFs cell lines upon the Rint1 knock-down 
does not resemble apoptosis, since no typical apoptotic features, such as apoptotic 
nuclear fragmentation, intranucleosomal cleavage of chromatin, caspase-3 proteasomal 
cleavage (activation) or cleavage of PARP1 were observed. It does not however relate to 
DNA damage-induced response and cell cycle arrest. Further experiments are necessary 
to delineate cell death modality and signaling pathways triggered by a Rint1 deficiency in 
MEFs (e. g. mitotic catastrophe, ER stress-induced cell death or other cell death forms). 
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8.2. Analysis of sequence conservation among RINT1 homologs 
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